Ligand-drug conjugate and use thereof
By combining ligand drug conjugates with low toxic repair inhibitors and high toxic damage agents, the targeted nature of antibodies is used to accurately place toxins on tumor cells, solving the poor effect of existing ADC treatment and the risk of killing normal cells. The problem has achieved higher tumor suppression effect and a larger treatment window.
Patent Information
- Application Number
- PCT/CN2023/094714
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-18
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-14
AI Technical Summary
The existing antibody drug conjugates (ADCs) have limited toxin release and killing efficiency when treating tumors, resulting in poor treatment effects and a high risk of killing normal cells.
Design a ligand drug conjugate to combine low toxic repair inhibitors with high toxic damage agents, use the targeting of antibodies to accurately deliver them to tumor cells, and use the combination of DNA damage repair inhibitors and other drugs. Enhance the killing activity and targeting of toxins.
It significantly improves the tumor inhibitory effect on tumor cells, reduces the risk of killing normal cells, expands the treatment window, and improves the treatment effect.
Smart Images

Figure CN2023094714_14112024_PF_FP_ABST
Abstract
Description
Ligand-drug conjugates and their applications Technical Field
[0001] The present disclosure relates to the field of medical technology, and in particular to ligand-drug conjugates and applications thereof. Background Art
[0002] Antibody-drug conjugates (ADCs) are a new class of macromolecules that combine the potent lethality of small molecule drugs with the highly specific targeting properties of antibodies. Leveraging the specificity of antibodies, they precisely deliver drugs to tumors and / or tumor cells, avoiding damage to normal cells in the body and thus minimizing adverse reactions during treatment. ADCs consist of three components: an antibody (antibody), a toxin (drug), and a linker. When the antibody portion of an ADC specifically binds to a specific antigen on the surface of a tumor cell, the tumor cell membrane indents, forming endosomes that engulf the ADC. This process is known as internalization. The antibody portion of the ADC, or linker, is then degraded by enzymes within the cell, releasing the toxin, which then begins to kill tumor cells. In ADC drug development, the "linker + toxin" (payload) is a crucial intermediate, consisting of a linker and a cytotoxic molecule (drug). Currently, toxins in payloads primarily include tubulin inhibitors and topoisomerase inhibitors.
[0003] Summary of the Invention
[0004] In order to improve the therapeutic effect of ligand-drug conjugates (such as antibody-drug conjugates ADC) and increase the therapeutic window, the present disclosure provides a ligand-drug conjugate shown in Formula I or its stereoisomers, prodrugs, pharmaceutically acceptable salts or pharmaceutically acceptable solvates. The ligand-drug conjugate is coupled with two different toxins, namely a repair inhibitor with low toxicity and low killing activity and a damaging agent with high killing activity; the ligand (such as an antibody) is simultaneously coupled with a low-toxicity repair inhibitor and a highly toxic damaging agent, and the resulting dual-toxic ADC drug has higher killing activity than the ADC in which the ligand (such as an antibody) is coupled with a single toxin. The ligand-drug conjugate (such as a dual-toxic ADC) of the present application has a significantly stronger anti-tumor effect at the cellular level.
[0005] To this end, in the first aspect of the present disclosure, the present disclosure provides a ligand-drug conjugate represented by formula I or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
[0006] in:
[0007] Ab is a targeting moiety selected from an antibody, an antibody fragment, a targeting protein or an Fc-fusion protein;
[0008] D1 is a first drug, which is connected to L1;
[0009] D2 is a second drug, the second drug is selected from a DNA damage repair inhibitor, and the second drug is connected to L2;
[0010] L1 is a first linking unit, which connects the first drug and the targeting moiety;
[0011] L2 is a second linking unit, which connects the second drug and the targeting moiety;
[0012] m is an integer selected from 0-20 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20);
[0013] n is selected from an integer of 1-20 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20).
[0014] In some embodiments, the second drug is selected from ATR inhibitors, ATM inhibitors, PARP inhibitors, WEE1 inhibitors, CHK1 inhibitors, DNA-PK inhibitors.
[0015] In some embodiments, the ATR inhibitor is selected from 、 Or a compound represented by formula A or a deuterated substance thereof: Wherein, X1 is selected from O, S, NH, CH2; X2 and X3 are each independently selected from N, CH; X4, X5, and X6 are each independently selected from N, CH; X7 is selected from N, C(R o );R o Selected from hydrogen, C1-C6 alkyl, R b R a N-;R a 、R b Each is independently selected from hydrogen, C1-C6 alkyl; R1, R2, R3, R4, R5 are each independently selected from hydrogen, C1-C6 alkyl, R c R6, R7, R8, and R9 are each independently selected from hydrogen, C1-C6 alkyl; R dis selected from hydrogen, C1-C6 alkyl; p is selected from 1, 2, 3, 4, 5, 6. In some embodiments, X1 is selected from O, S. In some embodiments, X1 is O. In some embodiments, X2 is N, X3 is CH. In some embodiments, X4, X6 are N, X5 is CH. In some embodiments, X7 is C(Ro). In some embodiments, R o R b R a N-. In some embodiments, R a 、R b All are hydrogen.
[0016] In some embodiments, R1, R2, R3, R4, and R5 are each independently selected from hydrogen,
[0017] In some embodiments, any one of R1, R2, R3, R4, and R5 is The remainder is hydrogen.
[0018] In some embodiments, R3 is R1, R2, R4, and R5 are hydrogen.
[0019] In some embodiments, R c Selected from C1-C6 alkyl.
[0020] In some embodiments, R c It is isopropyl.
[0021] In some embodiments, R6, R7, R8, and R9 are hydrogen.
[0022] In some embodiments, R d Selected from C1-C6 alkyl.
[0023] In some embodiments, R d It is a methyl group.
[0024] In some embodiments, p is selected from 1, 2, and 3.
[0025] In some embodiments, p is 1.
[0026] In some embodiments, the compound represented by formula A is
[0027] In some embodiments, the PARP inhibitor is selected from
[0028] In some embodiments, the ATM inhibitor is selected from
[0029] In some embodiments, the WEE1 inhibitor is selected from
[0030] In some embodiments, the CHK1 inhibitor is selected from
[0031] In some embodiments, the DNA-PK1 inhibitor is selected from
[0032] In some embodiments, the second linking unit is a cleavable or non-cleavable linking unit.
[0033] In some embodiments, L2 is L 21 -L 22 -L 23 -L 24 , and L 24 Connected to D2, L 21 Linked to Ab (preferably, L 21 coupled to Ab via thiol groups),
[0034] L 21 Selected from And the N-terminal and L 22 Connected,
[0035] L 22 Selected from: The carbonyl end and L 23 connected;
[0036] L 23 is selected from amino acid residues or peptide residues consisting of 2-10 amino acid residues, and the carbonyl end is connected to L 24 connected;
[0037] L 24 for Or direct key, and L 24 for When , the carbonyl end is connected to D2.
[0038] In some embodiments, L 23 It is a peptide residue consisting of 2-4 (preferably 2) amino acid residues, and the carbonyl end is connected to L 24 Preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, lysine, citrulline, serine, glutamic acid, and aspartic acid, and more preferably, the amino acid is selected from valine, alanine, and citrulline.
[0039] In some embodiments, L 23 Selected from valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and the carbonyl end is connected to L 24 are connected.
[0040] In some embodiments, L 23 Selected from The carbonyl end and L 24 are connected.
[0041] In some embodiments, L2 is selected from:
[0042] And the carbonyl end is connected to D2.
[0043] In some embodiments, wherein D2-L2- is selected from:
[0044] In some embodiments, the first drug is selected from, but not limited to, a tubulin-binding agent, a DNA-damaging agent, an enzyme inhibitor, an immunomodulatory agent, a peptide, or a nucleotide.
[0045] In some embodiments, the first drug is selected from:
[0046] a) Alkylating agents, PBD and its derivatives, chlorpheniramine, chlorpheniramine, cyclophosphamide, dacarbazine, estradiol nitrogen mustard, ifosfamide, mechlorethamine, dimethoxamine hydrochloride, nitrogen oxide mustard, amlodipine hydrochloride, mycophenolic acid, dulcitol, pipobroman, mechlorethamine, phenacetin, phenylephrine, thiotepa, trofosfamide, uracil; CC-1065; duocarmycin; benzodiazepine dimers; nitrosoureas; alkyl sulfonates; triazenes; platinum-containing compounds; aziridines, such as chromanone, carlosin, metodipa and uredopa; ethyleneimine and methylmelamine, including hexamethylmelamine, triethylenetriamine, triethylphosphoramide, triethylenethiophosphoramide and trishydroxymethylmethylamine and their derivatives and deuterated derivatives;
[0047] b) Plant alkaloids, vinca alkaloids; taxoids and their analogs; maytansine alkaloids and their analogs; cryptophycin; epothilone, damascene, dimolide, bryozoan lactone, dolastatin, auristatins, tubulysin, cephalostatin, pancratistatin, sarcodictyin, spongestatin, Monomethyl auristatin E (MMAE), Monomethyl auristatin F (MMAF), maytansinoids (e.g., Maytansine DM1, Maytansine DM4), amatoxin and its derivatives and deuterated derivatives;
[0048] c) DNA topoisomerase inhibitors, etoposide, 9-aminocamptothecin, camptothecin, clinatadole, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novoglobulin, retinoic acid, teniposide, topotecan, 9-nitrocamptothecin, SN38, mitomycin and its derivatives and deuterated derivatives;
[0049] d) Antimetabolites, antifolates, DHFR inhibitors; MP dehydrogenase inhibitors; ribonucleotide reductase inhibitors; pyrimidine analogs, uracil analogs; cytosine analogs; purine analogs; folic acid supplements;
[0050] e) Hormone therapy agents, receptor antagonists, antiestrogens, LHRH agonists; antiandrogens; retinoids, vitamin D3 analogs; photodynamic therapy agents; cytokines, human proteins including TNF and their derivatives and deuterated derivatives;
[0051] f) kinase inhibitors, BIBW2992, imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080, mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, ispinax and their derivatives and deuterated derivatives;
[0052] g) antibiotics, enediyne antibiotics, aclacinomycins, actinomycins, anthramycin, azaserine, bleomycin, canomycin, karanomycin, carminomycin, carmophorin, doxorubicin, morpholinodoxorubicin, 2-pyrrolinodoxorubicin and deoxydaunorubicin, epirubicin, aclarubicin, idarubicin, marcomycin, mycophenolic acid, lopinomycin, peplomycin, puromycin, triferric doxorubicin, streptozotocin, streptozotocin, tuberculin, ubenimex, jinsistatin, daurubicin, PNU-159682 and their derivatives and deuterated derivatives;
[0053] h) Polyketides, in particular bullatacin and bullatacinone; gemcitabine, cyclooxygenase, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allocatin-7, Xegeva, Provenge, Yervoy, prenylation inhibitors, dopaminergic neurotoxins, actinomycin, bleomycin, anthracyclines, doxorubicin, idarubicin, epirubicin, doxyrubicin, mitoxantrone, MDR inhibitors, Ca2+ ATPase inhibitors, histone deacetylase inhibitors; celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A. Antiadrenal drugs, such as aminoglutethimide, mitotane, trilostane, aceglucuronolide, aldophosphamide, aminolevulinic acid, amsacrine, arabinoside, bestrAbuci, bisantrene, edatraxate, defofamine, mecocin, diazocine, eflornithine, elfornithine, elliptonium acetate, ethylgluconate, gallium nitrate, cytosine, hydroxyurea, ibandronate, lentinan, lonidamine, mitoguanidine, mitoxantrone, mopidarol, diamine nitrazepam, pentostatin, methamidine, pirarubicin, podophyllic acid, 2-ethylhydrazine, and methylprocarbazine; Piperazinedionepropane; rhizoxin; siroxicam; spirogermanium; tricrosporin; triiminoquinone; trichlorotriethylamine; trichothecenes, polyurethanes, siRNA and antisense drugs and their derivatives and deuterated derivatives.
[0054] In some embodiments, the first drug D1 is selected from a camptothecin structural compound or a deuterated compound thereof.
[0055] In some embodiments, the camptothecin-like compound has a structure shown in Formula B,
[0056] in:
[0057] The chiral carbon atom No. 1 connected to the N atom has an absolute chirality of R configuration or S configuration;
[0058] R' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, aryl, substituted aryl, or heteroaryl;
[0059] R 1 ' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, carboxyl, heterocyclyl, aryl, substituted aryl or heteroaryl;
[0060] R 2 ' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, carboxyl, heterocyclyl, aryl, substituted aryl or heteroaryl;
[0061] X' is selected from -C(O)-(CR 3 'R 4 ')t-CR a 'R b '-O-、-C(O)-(CR 3 'R 4 ')t-CR a 'R b '-NH- or -C(O)-(CR 3 'R 4 ')t-CR a 'R b '-S-, preferably, the carbonyl end is connected to the N atom;
[0062] R a ' is selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl, substituted aryl or heteroaryl;
[0063] R b ' is selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl, substituted aryl or heteroaryl;
[0064] Or, R a '、R b ' and the carbon atom to which it is connected constitutes a C3-6 cycloalkyl group, a cycloalkylalkyl group or a heterocyclic group;
[0065] R 3 '、R 4 ' are the same or different and are each independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, alkoxy, hydroxy, amino, cyano, nitro, hydroxyalkyl, cycloalkyl or heterocyclyl;
[0066] Or, R3 '、R 4 ' and the carbon atom to which it is connected constitutes a C3-6 cycloalkyl group, a cycloalkylalkyl group or a heterocyclic group;
[0067] The wavy line on the right side connected to X' is connected to L1;
[0068] t is selected from an integer of 0-4 (eg, 0, 1, 2, 3, or 4).
[0069] In some embodiments, R' is selected from hydrogen, C1-C6 alkyl.
[0070] In some embodiments, R' is hydrogen.
[0071] In some embodiments, R 1 ' is selected from hydrogen, C1-C6 alkyl.
[0072] In some embodiments, R 1 ' is selected from C1-C6 alkyl.
[0073] In some embodiments, R 1 ' is a methyl group.
[0074] In some embodiments, R 2 ' is selected from halogen.
[0075] In some embodiments, R 2 ' is fluorine.
[0076] In some embodiments, X' is selected from -C(O)-(CR 3 'R 4 ')t-CR a 'R b '-O-, preferably, the carbonyl end is connected to the N atom.
[0077] In some embodiments, X' is selected from -C(O)-CR a 'R b '-O-, preferably, the carbonyl end is connected to the N atom.
[0078] In some embodiments, R a ' is selected from hydrogen, C1-C6 alkyl.
[0079] In some embodiments, R a ' is hydrogen.
[0080] In some embodiments, R b ' is selected from hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl.
[0081] In some embodiments, R b' is selected from hydrogen, deuterium, methyl, cyclopropyl, trifluoromethyl.
[0082] In some embodiments, t is 0.
[0083] In some embodiments, X' is selected from the following structures without limitation:
[0084] in:
[0085] Chiral carbon atom No. 2 has absolute chirality of R configuration or S configuration;
[0086] The left wavy line is connected to N of the compound represented by formula B, and the right wavy line is connected to L1.
[0087] In some embodiments, the compound represented by formula B is selected from
[0088] In some embodiments, the first drug is selected from
[0089] In some embodiments, the first linking unit is a cleavable or non-cleavable linking unit.
[0090] In some embodiments, L1 is L 11 -L 12 -L 13 -L 14 , and L 14 Connected to D1, L 11 Linked to Ab (preferably, L 11 coupled to Ab via thiol groups),
[0091] L 11 Selected from And the N-terminal and L 12 Connected,
[0092] L 12 Selected from: The carbonyl end and L 13 or L 14 connected;
[0093] L 13 is selected from a direct bond, an amino acid residue or a peptide residue consisting of 2-10 amino acid residues, and L 13 When selected from amino acid residues or peptide residues consisting of 2-10 amino acid residues, the carbonyl end is connected to L 14 connected;
[0094] L14 Selected from The amino terminus is connected to L 13 or L 12 The carbonyl end or carbon end is connected to D1.
[0095] In some embodiments, L 13 is selected from a direct bond, an amino acid residue, a peptide residue consisting of 2-4 amino acid residues, and L 13 When selected from amino acid residues, peptide residues consisting of 2-4 amino acid residues, the carbonyl end and L 14 Preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, lysine, citrulline, serine, glutamic acid, and aspartic acid, and more preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, citrulline, and lysine.
[0096] In some embodiments, L 13 is selected from a direct bond, lysine, glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and L 13 When selected from lysine, glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), the carbonyl end is connected to L 14 are connected.
[0097] In some embodiments, L 13 Select from direct keys, And L 13 Selected from When the carbonyl end is connected to L 14 are connected.
[0098] In some embodiments, L1 is selected from:
[0099] The carbonyl end or The carbon end at one end is connected to D1.
[0100] In some embodiments, D1-L1- is selected from the group consisting of:
[0101] In some embodiments, m is selected from an integer of 1-10.
[0102] In some embodiments, m is selected from an integer of 2-8.
[0103] In some embodiments, m is selected from 2, 4, and 8.
[0104] In some embodiments, n is selected from an integer of 1-10.
[0105] In some embodiments, n is selected from an integer of 2-8.
[0106] In some embodiments, n is selected from 2, 4, and 8.
[0107] In some embodiments, Ab is selected from a murine antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an antibody fragment, a bispecific antibody, and a multispecific antibody.
[0108] In some embodiments, Ab forms a linkage to the Linker through its cysteine sulfhydryl group (—SH).
[0109] In some embodiments, Ab is an antibody, which is a monoclonal antibody selected from the group consisting of: anti-EGFRvIII antibody, anti-DLL-3 antibody, anti-PSMA antibody, anti-CD70 antibody, anti-MUC16 antibody, anti-ENPP3 antibody, anti-TDGF1 antibody, anti-ETBR antibody, anti-MSLN antibody, anti-TIM-1 antibody, anti-LRRC15 antibody, anti-LIV-1 antibody, anti-CanAg / AFP antibody, anti-cladin 18.2 antibody, anti-Mesothelin antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-c-MET antibody, anti-SLITRK6 antibody, anti-KIT / CD117 antibody, anti-STEAP1 antibody, anti-SLAMF7 / CS1 antibody, anti-NaPi2B / SLC34A2 antibody, anti-GPNMB antibody, anti-HER3 (ErbB3) antibody, anti-MUC1 / CD227 antibody, anti-AXL antibody, anti-CD166 antibody, anti-B7-H3 (CD276) antibody, anti-PTK7 / CCK4 antibody, anti-PRLR antibody, anti-EFNA4 antibody, anti-5T4 antibody, anti-NOTCH3 antibody, anti-Nectin 4 antibody, anti-TROP-2 antibody, anti-CD142 antibody, anti-CA6 antibody, anti-GPR20 antibody, anti-CD174 antibody, anti-CD71 antibody, anti-EphA2 antibody, anti-LYPD3 antibody, anti-FGFR2 antibody, anti-FGFR3 antibody, anti-FRα antibody, anti-CEACAMs antibody, anti-GCC antibody, anti-Integrin Av antibody, anti-CAIX antibody, anti-P-cadherin antibody, anti-GD3 antibody, anti-Cadherin 6 antibody, anti-LAMP1 antibody, anti-FLT3 antibody, anti-BCMA antibody, anti-CD79b antibody, anti-CD19 antibody, anti-CD33 antibody, anti-CD56 antibody, anti-CD74 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD37 antibody, anti-CD47 antibody, anti-CD138 antibody, anti-CD352 antibody, anti-CD25 antibody, or anti-CD123 antibody.
[0110] In some embodiments, Ab is an antibody selected from the group consisting of anti-CD33 antibody ANTI-CD33, anti-Trop2 antibody ANTI-Trop2-1, anti-Trop2 antibody ANTI-Trop2-2, anti-HER2 antibody Trastuzumab (Tras), and anti-HER2 antibody Tras-016, and the relevant sequences are as follows:
[0111] Sequence of anti-CD33 antibody ANTI-CD33
[0112] >Light chain -LC
[0113] >Heavy chain-HC
[0114] Sequence of anti-Trop2 antibody ANTI-Trop2-1
[0115] >Light chain -LC
[0116] >Heavy chain-HC
[0117] Sequence of anti-Trop2 antibody ANTI-Trop2-2
[0118] >Light chain -LC
[0119] >Heavy chain-HC
[0120] Sequence of the anti-HER2 antibody Trastuzumab (Tras)
[0121] >Light chain -LC
[0122] >Heavy chain-HC
[0123] Sequence of the anti-HER2 antibody Tras-016
[0124] >Light chain -LC
[0125] >Heavy chain-HC
[0126] In some embodiments, both D1-L1- and D2-L2- are coupled to Ab via sulfhydryl groups.
[0127] In some embodiments, the source of the thiol group is selected from: the thiol group on the cysteine residue formed after the original interchain disulfide bond of the targeting portion is reduced, the thiol group on the cysteine after site-directed mutation of some original amino acids on the targeting portion into cysteine, the thiol group on the cysteine after site-directed insertion of cysteine into the targeting portion, and the thiol group on the cysteine after site-directed insertion of a cysteine-containing polypeptide into the targeting portion.
[0128] In some embodiments, D1-L1- and D2-L2- are each coupled to Ab via sulfhydryl groups from different sources.
[0129] In some embodiments, any one of D1-L1- and D2-L2- is coupled to Ab through the thiol group on the cysteine residue formed after the original interchain disulfide bond of the targeting moiety is reduced, and the other is coupled to Ab through the thiol group on the cysteine after site-directed mutation of some original amino acids on the targeting moiety into cysteine, or the thiol group on the cysteine after site-directed insertion of cysteine into the targeting moiety, or the thiol group on the cysteine after site-directed insertion of a cysteine-containing polypeptide into the targeting moiety.
[0130] In some embodiments, the ligand drug conjugate is selected from:
[0131] Ab-R01(2)-Ex01(8),
[0132] Ab-R01(8)-Ex01(2),
[0133] Ab-R01(4)-Ex01(4),
[0134] Ab-R01(4)-Ex01(8),
[0135] Ab-R01(8)-Ex01(4),
[0136] Ab-R01(2)-Ex02(8),
[0137] Ab-R01(8)-Ex02(2),
[0138] Ab-R01(4)-Ex02(4),
[0139] Ab-R01(2)-Ex03(8),
[0140] Ab-R01(8)-Ex03(2),
[0141] Ab-R01(4)-Ex03(4),
[0142] Ab-R01(2)-Ex04(8),
[0143] Ab-R01(8)-Ex04(2),
[0144] Ab-R01(4)-Ex04(4),
[0145] Ab-R01(2)-Ex05(8),
[0146] Ab-R01(8)-Ex05(2),
[0147] Ab-R01(4)-Ex05(4),
[0148] Ab-R01(2)-Ex06(8)、
[0149] Ab-R01(8)-Ex06(2)、
[0150] Ab-R01(4)-Ex06(4)、
[0151] Ab-R01-1(2)-Ex01(8)、
[0152] Ab-R01-1(8)-Ex01(2)、
[0153] Ab-R01-1(4)-Ex01(4)、
[0154] Ab-R01-1(8)-Ex01(4)、
[0155] Ab-R01-1(4)-Ex01(8)、
[0156] Ab-R01-1(2)-Ex02(8)、
[0157] Ab-R01-1(8)-Ex02(2)、
[0158] Ab-R01-1(4)-Ex02(4)、
[0159] Ab-R01-1(2)-Ex03(8)、
[0160] Ab-R01-1(8)-Ex03(2)、
[0161] Ab-R01-1(4)-Ex03(4)、
[0162] Ab-R01-1(2)-Ex04(8)、
[0163] Ab-R01-1(8)-Ex04(2)、
[0164] Ab-R01-1(4)-Ex04(4)、
[0165] Ab-R01-1(2)-Ex05(8)、
[0166] Ab-R01-1(8)-Ex05(2)、
[0167] Ab-R01-1(4)-Ex05(4)、
[0168] Ab-R01-1(2)-Ex06(8)、
[0169] Ab-R01-1(8)-Ex06(2)、
[0170] Ab-R01-1(4)-Ex06(4)、
[0171] Ab-R01-1(2)-PB01(8)、
[0172] Ab-R01-1(2)-PB02(8)、
[0173] Ab-R01-1(8)-PNU01(2)、
[0174] Ab-R01-1(8)-PNU02(2)、
[0175] Ab-R01-1(2)-CBI01(8)、
[0176] Ab-R01-1(2)-CBI02(8)、
[0177] Ab-R01-1(2)-CBI03(8)、
[0178] Ab-R01-1(2)-PBD01(8)、
[0179] Ab-R01-1(2)-PBD02(8)、
[0180] Ab-R01-1(2)-PBD-CBI01(8)、
[0181] Ab-R01-1(2)-PBD-CBI02(8)、
[0182] Ab-R01-1(8)-M01(2)、
[0183] Ab-R01-1(8)-M02(2)、
[0184] Ab-R01-1(8)-M03(2)、
[0185] Ab-AT01(2)-Ex01(8)、
[0186] Ab-AT02(2)-Ex01(8)、
[0187] Ab-AT03(2)-Ex01(8)、
[0188] Ab-AT04(2)-Ex01(8)、
[0189] Ab-TA01(2)-Ex01(8)、
[0190] Ab-VE01(2)-Ex01(8)、
[0191] Ab-E01(2)-Ex01(8),
[0192] Ab-RU01(2)-Ex01(8),
[0193] Ab-PA01(2)-Ex01(8),
[0194] Ab-CEP01(2)-Ex01(8),
[0195] Ab-TM01(2)-Ex01(8),
[0196] Ab-TM02(2)-Ex01(8),
[0197] Ab-WE01(2)-Ex01(8),
[0198] Ab-CH01(2)-Ex01(8),
[0199] Ab-CH02(2)-Ex01(8),
[0200] Ab-CH03(2)-Ex01(8),
[0201] Ab-CH04(2)-Ex01(8),
[0202] Ab-DP01(2)-Ex01(8),
[0203] Ab-DP02(2)-Ex01(8),
[0204] Ab-DP03(2)-Ex01(8).
[0205] The meaning of the structural formula of the above ligand drug conjugates, for example, Ab-R01(2)-Ex01(8), represents the ligand drug conjugate shown in formula I. In the example, D2-L2- is R01. D1-L1- is Ex01 The number of D1-L1- coupled to Ab is 8, i.e., m is 8, and the number of D2-L2- coupled to Ab is 2, i.e., n is 2. The meanings of the structural formulas of the remaining ligand-drug conjugates can be understood by referring to the above content.
[0206] In a second aspect of the present disclosure, the present disclosure provides a drug-linker conjugate, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein the drug-linker conjugate is selected from the following:
[0207] In the third aspect of the present disclosure, the present disclosure provides a pharmaceutical composition comprising the aforementioned ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned drug-linker conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, and optionally one or more pharmaceutical excipients.
[0208] In the fourth aspect of the present disclosure, the present disclosure provides the use of the aforementioned ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned drug-linker conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned pharmaceutical composition in the preparation of a drug for treating and / or preventing a disease, wherein the disease is cancer.
[0209] In some embodiments, the cancer is selected from skin cancer, lymphoma, esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, kidney cancer, solid tumors, non-Hodgkin's lymphoma, central nervous system tumors (e.g., glioma, glioblastoma multiforme, neuroblastoma, glioma or sarcoma), melanoma, prostate cancer, thyroid cancer, bone cancer, urethral cancer, salivary gland cancer, leukemia (e.g., acute myeloid leukemia), and other solid tumors and blood tumors.
[0210] In some embodiments, the cancer is selected from lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, and kidney cancer.
[0211] In the fifth aspect of the present disclosure, the present disclosure provides the aforementioned ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned drug-linker conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned pharmaceutical composition, which is used to treat and / or prevent a disease, wherein the disease is cancer.
[0212] In some embodiments, the cancer is selected from skin cancer, lymphoma, esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, kidney cancer, solid tumors, non-Hodgkin's lymphoma, central nervous system tumors (e.g., glioma, glioblastoma multiforme, neuroblastoma, glioma or sarcoma), melanoma, prostate cancer, thyroid cancer, bone cancer, urethral cancer, salivary gland cancer, leukemia (e.g., acute myeloid leukemia), and other solid tumors and blood tumors.
[0213] In some embodiments, the cancer is selected from lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, and kidney cancer.
[0214] In the sixth aspect of the present disclosure, the present disclosure provides a method for preventing and / or treating a disease, wherein the disease is cancer, the method comprising: administering to an individual in need thereof a preventive and / or therapeutically effective amount of the aforementioned ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned drug-linker conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate, or the aforementioned pharmaceutical composition.
[0215] In some embodiments, the cancer is selected from skin cancer, lymphoma, esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, kidney cancer, solid tumors, non-Hodgkin's lymphoma, central nervous system tumors (e.g., glioma, glioblastoma multiforme, neuroblastoma, glioma or sarcoma), melanoma, prostate cancer, thyroid cancer, bone cancer, urethral cancer, salivary gland cancer, leukemia (e.g., acute myeloid leukemia), and other solid tumors and blood tumors.
[0216] In some embodiments, the cancer is selected from lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, and kidney cancer.
[0217] Definition of terms
[0218] In this disclosure, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of this disclosure, definitions and explanations of relevant terms are provided below.
[0219] In the present disclosure, examples of the term "pharmaceutically acceptable salt" include organic acid addition salts formed from organic acids that form pharmaceutically acceptable anions, including but not limited to formates, acetates, propionates, benzoates, maleates, fumarates, succinates, tartrates, citrates, ascorbates, α-ketoglutarate, α-glycerophosphates, alkylsulfonates, or arylsulfonates; preferably, the alkylsulfonate is methylsulfonate or ethylsulfonate; and the arylsulfonate is benzenesulfonate or p-toluenesulfonate. Suitable inorganic salts may also be formed, including but not limited to hydrochlorides, hydrobromides, hydroiodides, nitrates, bicarbonates, carbonates, sulfates, or phosphates.
[0220] Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example, by reacting a sufficient amount of a basic compound with a suitable acid affording a pharmaceutically acceptable anion.
[0221] In the present disclosure, the term "prodrug" refers to a derivative that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide a compound of the present invention. Prodrugs become active compounds only through this reaction under biological conditions, or they do not have or only have relatively low activity in their unreactive form. Prodrugs can generally be prepared using known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff, 5th edition).
[0222] When the stereoisomers in the compounds described in the present disclosure are specifically designated as (R)- or (S)-isomers in the chemical name, it should be understood that the predominant configuration is the (R)-isomer or the (S)-isomer, respectively. Any asymmetric carbon atom may exist in the (R)-, (S)-, or (R, S)-configuration, preferably in the (R)- or (S)-configuration.
[0223] In this disclosure, "solvate" or "solvate" are used interchangeably to refer to a compound that exists in combination with a solvent molecule. The combination may include a stoichiometric amount of a solvent, such as a monohydrate or dihydrate, or may include any amount of water; for example, methanol or ethanol may form an "alcoholate," which may also be stoichiometric or non-stoichiometric. The term "solvate" as used herein refers to a solid form, i.e., a compound in solution in a solvent, which may be solvated but is not a solvate as the term is used herein.
[0224] In the present disclosure, "deuterated compound" refers to a compound in which one or more hydrogen atoms are replaced by deuterium atoms.
[0225] For the purposes of this disclosure, pharmaceutical excipients refer to excipients and additives used in the production of pharmaceuticals and the preparation of prescriptions. These substances, in addition to the active ingredients, have been reasonably evaluated for safety and are included in pharmaceutical preparations. In addition to providing shape, acting as carriers, and improving stability, pharmaceutical excipients also have important functions such as solubilization, dissolution enhancement, and sustained-release control. They are important components that may affect the quality, safety, and efficacy of drugs. Based on their source, they can be categorized as natural, semi-synthetic, and fully synthetic. According to their functions and uses, they can be divided into: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoaming agents, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, release retardants, etc. According to their route of administration, they can be divided into oral, parenteral, mucosal, transdermal or topical administration, nasal or oral inhalation administration, and ocular administration, etc. The same pharmaceutical excipient can be used in pharmaceutical preparations for different routes of administration and have different functions and uses.
[0226] In the present disclosure, the pharmaceutical composition can be prepared into various suitable dosage forms according to the route of administration, such as tablets, capsules, granules, oral solutions, oral suspensions, oral emulsions, powders, tinctures, syrups, injections, suppositories, ointments, creams, pastes, ophthalmic preparations, pills, implants, aerosols, powder sprays, sprays, etc. The pharmaceutical composition or suitable dosage form can contain 0.01 mg to 1000 mg of the compound of the present disclosure or a pharmaceutically acceptable salt or conjugate thereof, preferably 0.1 mg to 800 mg, preferably 0.5-500 mg, preferably 0.5 to 350 mg, and particularly preferably 1-250 mg.
[0227] The pharmaceutical composition can be administered in the form of an injection, including an injection solution, sterile powder for injection, and concentrated solution for injection. Among them, the carriers and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils such as monoglycerides or diglycerides can also be used as solvents or suspending media.
[0228] As used herein, the term "treat" generally refers to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in terms of completely or partially preventing a disease or its symptoms; and / or therapeutic, in terms of partially or completely stabilizing or curing a disease and / or causing side effects due to the disease. As used herein, "treat" encompasses any treatment of a disease in a patient, including: (a) preventing the onset of a disease or symptom in a patient who is susceptible to the disease or symptom but has not yet been diagnosed with the disease; (b) suppressing the symptoms of a disease, i.e., arresting its development; or (c) alleviating the symptoms of a disease, i.e., causing the disease or symptom to regress.
[0229] In the present disclosure, the term "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from a disease (e.g., a disease described herein) (referred to as a patient) or normal individuals. The term "non-human animal" in the present disclosure includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0230] As used herein, the term "effective amount" refers to that amount of a compound which, when administered, will relieve to some extent one or more of the symptoms of the condition being treated.
[0231] In this disclosure, the term "targeting moiety" refers to a portion of a conjugate that is capable of specifically binding to a target (or portion of a target) on the cell surface. Through the interaction of the targeting moiety with the target, the conjugate can be delivered to a specific cell population. Preferably, the targeting moiety is an antibody.
[0232] In this disclosure, the term "antibody" is used in its broadest sense, including complete monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies) formed by at least two complete antibodies, as long as they have the desired biological activity. In this disclosure, "antibody" and "immunoglobulin" can be used interchangeably.
[0233] In this disclosure, the term "monoclonal antibody" refers to an antibody derived from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations. Monoclonal antibodies have high specificity for a single determinant (epitope) of an antigen, whereas polyclonal antibodies, in contrast, comprise different antibodies directed against different determinants (epitopes). In addition to their specificity, monoclonal antibodies have the advantage of being synthesized without contamination by other antibodies. The modifier "monoclonal" herein indicates that the antibody is characterized by being derived from a substantially homogeneous population of antibodies and should not be construed as requiring production by a specific method.
[0234] In some embodiments of the present disclosure, monoclonal antibodies also specifically include chimeric antibodies, that is, a portion of the heavy chain and / or light chain is identical or homologous to a certain type, class, or subclass of antibody, and the remaining portion is identical or homologous to another type, class, or subclass of antibody, as long as they have the desired biological activity (see, for example, US 4,816,567; and Morrison et al., 1984, PNAS, 81: 6851-6855). Chimeric antibodies that can be used in the present disclosure include primatized antibodies, which contain variable region antigen-binding sequences from non-human primates (e.g., monkeys, orangutans, etc.) and human constant region sequences.
[0235] In this disclosure, the term "antibody fragment" refers to a portion of an antibody, preferably the antigen binding region or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementarity determining region fragments, diabodies, linear antibodies and single-chain antibody molecules.
[0236] In the present disclosure, the term "bispecific antibody" is also referred to as "bifunctional antibody conjugate", which refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) through a coupling arm. The conjugate retains the activity of each antibody and thus has bifunctionality and bispecificity.
[0237] In the present disclosure, the term "multispecific antibody" includes, for example, trispecific antibodies and tetraspecific antibodies, the former being antibodies with three different antigen-binding specificities and the latter being antibodies with four different antigen-binding specificities.
[0238] In the present disclosure, the term "intact antibody" refers to an antibody comprising an antigen-binding variable region and a light chain constant region (CL), a heavy chain constant region (CH1, CH2, and CH3). The constant region can be a native sequence (e.g., a human native constant region sequence) or an amino acid sequence variant thereof. An intact antibody is preferably an intact antibody having one or more effector functions.
[0239] In the present disclosure, the "humanized" form of a non-human (e.g., mouse) antibody refers to a chimeric antibody that contains a minimal amount of non-human immunoglobulin sequence. Most humanized antibodies are those in which the hypervariable region residues of a human recipient immunoglobulin are replaced with non-human (e.g., mouse, rat, rabbit, or non-human primate) hypervariable region residues (donor antibody) having the desired specificity, affinity, and function. In some embodiments, the framework region (FR) residues of the human immunoglobulin are also replaced with non-human residues. Moreover, the humanized antibody may also include residues that are not present in the recipient antibody or the donor antibody. These modifications are intended to further optimize the performance of the antibody. Humanized antibodies generally include at least one, typically two, variable regions in which all or nearly all of the hypervariable loops correspond to those of a non-human immunoglobulin, while the FRs are entirely or almost entirely human immunoglobulin sequences. The humanized antibody may also include at least a portion of an immunoglobulin constant region (Fc, typically a human immunoglobulin Fc). For details, see, for example, Jones et al., 1986, Nature, 321:522-525; Riechmann et al., 1988, Nature, 332:323-329; and Presta, 1992, Curr Op Struct Bwl 2:593-596.
[0240] The monoclonal antibodies used in the present disclosure can be produced by a variety of methods. For example, the monoclonal antibodies used in the present disclosure can be obtained by the hybridoma method using cells from many species (including mouse, hamster, rat and human) (see, for example, Kohler et al., 1975, Nature, 256:495), or can be made by recombinant DNA technology (see, for example, US 4,816,567), or can be isolated from phage antibody libraries (see, for example, Clackson et al., 1991, Nature, 352:624-628; and Marks et al., 1991, Journal of Molecular Biology, 222:581-597).
[0241] In this disclosure, unless otherwise expressly stated, the descriptions “each independently selected from” and “each independently selected from” used throughout this document are interchangeable and should be understood in a broad sense. They can mean that in different groups, the specific options expressed by the same or different symbols do not affect each other, or that in the same group, the specific options expressed by the same or different symbols do not affect each other.
[0242] In the present disclosure, the structural formula shown in Formula A In which X7 is selected from N, C(R0), which represents that the structural formula shown in formula A is Other similar definitions can be understood by referring to the above content.
[0243] In this disclosure, the term "direct bond" means that the groups on both sides are directly connected. For example, L1 is L 11 -L 12 -L 13 -L 14 , if L 13 For direct keys, L1 is L 11 -L 12 -L 14 , that is, L 12 With L 14 Other similar definitions can be understood with reference to the above content.
[0244] Throughout this disclosure, substituents of the disclosed compounds are disclosed by group class or range. It is specifically noted that this disclosure includes every independent subcombination of the individual members of these group classes and ranges. For example, the term "C1-C6 alkyl" specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl groups.
[0245] In this disclosure, the term "alkyl" refers to a saturated aliphatic hydrocarbon group, including both branched and straight-chain groups, having a specified number of carbon atoms. For example, the term "C1-C6 alkyl" refers to a straight-chain or branched alkyl group containing 1 to 6 carbon atoms, including, for example, "C1-C3 alkyl" or "C1-C4 alkyl," methyl, ethyl, etc. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.
[0246] In the present disclosure, the term "C1-C4 alkyl" refers to a straight-chain or branched alkyl group containing 1-4 carbon atoms, including, for example, "C1-C3 alkyl", methyl, ethyl, etc. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
[0247] As used herein, the term "deuterated alkyl" refers to a group in which one or more hydrogen atoms in an alkyl group are replaced by a deuterium atom. The alkyl group may be a C1-C6 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group. Alkyl, C1-C6 alkyl, C1-C4 alkyl, or C1-C3 alkyl group are as defined above.
[0248] In the present disclosure, the term "haloalkyl" refers to a group obtained by replacing one or more hydrogen atoms in an alkyl group with a halogen. For example, it can be a "C1-C6 haloalkyl", which refers to a group obtained by replacing one or more hydrogen atoms in a C1-C6 alkyl group (e.g., a C1-C4 alkyl group, a C1-C3 alkyl group, etc.) with a halogen (preferably fluorine or chlorine), for example, a monofluoromethyl group, a difluoroethyl group, a trifluoromethyl group, etc. The definitions of alkyl, C1-C6 alkyl, C1-C4 alkyl, or C1-C3 alkyl group are as described above.
[0249] In the present disclosure, the term "hydroxyalkyl" refers to a group obtained by replacing one or more hydrogen atoms in an alkyl group with a hydroxyl group. For example, it can be a "C1-C6 hydroxyalkyl", which refers to a group obtained by replacing one or more hydrogen atoms in a C1-C6 alkyl group (e.g., a C1-C4 alkyl group, a C1-C3 alkyl group, etc.) with a hydroxyl group, for example, a hydroxymethyl group, a 2-hydroxyethyl group, etc. The definitions of alkyl, C1-C6 alkyl, C1-C4 alkyl, or C1-C3 alkyl group are as described above.
[0250] In the present disclosure, the term "alkoxy" refers to any of the above-mentioned alkyl groups (eg, C1-C6 alkyl, C1-C4 alkyl, C1-C3 alkyl, etc.) that is attached to the rest of the molecule through an oxygen atom (-O-).
[0251] In the present disclosure, the term "cycloalkyl" refers to a hydrocarbon group having a monocyclic ring system of a saturated carbocyclic ring, for example, it can be a C3-C6 cycloalkyl group, specifically cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0252] Halogen refers to fluorine, chlorine, bromine or iodine.
[0253] In this disclosure, the term "aryl" refers to substituted and unsubstituted aromatic 6-membered monocyclic groups, 10-membered bicyclic groups, and 10-membered or higher tricyclic groups, wherein all rings do not contain heteroatoms and are all ring carbon atoms. Specifically, aryl can be phenyl or naphthyl.
[0254] In the present disclosure, the term "heteroaryl" refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups, 8-, 9- or 10-membered bicyclic groups and 11- to 14-membered tricyclic groups having at least one heteroatom (N, O or S) in at least one ring, the heteroatom-containing ring optionally further having 1, 2 or 3 heteroatoms selected from N, O or S. Among them, substituted and unsubstituted aromatic 8-, 9- or 10-membered bicyclic groups and 11- to 14-membered tricyclic groups having at least one heteroatom (N, O or S) in at least one ring are "fused heteroaryl". For heteroaryl groups that are bicyclic or tricyclic, a bicyclic or tricyclic overall structure is required to form an aromatic system. The heteroaryl group can be attached on any available nitrogen or carbon atom of any ring. And it will be understood by those skilled in the art that two adjacent atoms (preferably carbon atoms) are shared between every two rings in the fused ring.
[0255] Exemplary monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, and the like.
[0256] Exemplary bicyclic heteroaryl groups include, but are not limited to, indolyl, 5-azaindolyl, pyrrolo[2,3-d]pyrimidinyl, 5,6-diazaindolyl, 6-azaindolyl, 7-azaindolyl, pyrazolo[3,4-b]pyridinyl, pyrrolo[2,3-c]pyridazinyl, thieno[2,3-d]imidazolyl, thieno[2,3-d]imidazolyl, pyrazolo[3,4-c]pyridinyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzothienyl, quinolinyl, isoquinolinyl, benzofuranyl, indolizinyl, quinoxalinyl, indazolyl, pyrrolopyrimidinyl, furopyridinyl, isoindolyl, and the like.
[0257] In this disclosure, the terms "heterocycle", "heterocyclic" or "heterocyclyl" are used interchangeably and refer to substituted and unsubstituted 3- to 7-membered (preferably 4-7 members, more preferably 5-6 members) monocyclic groups, 7- to 11-membered bicyclic groups and 10- to 15-membered tricyclic groups, which may contain one or more double bonds but do not constitute aromatic rings; wherein at least one ring has at least one heteroatom (N, O or S). The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated or partially saturated and do not constitute aromatic rings. The heterocyclic group may be attached at any available nitrogen or carbon atom.
[0258] Exemplary monocyclic heterocyclyl groups include azetidinyl, oxetanyl, pyrrolidinyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepanyl, 1-pyridonyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, 1,3-dioxolanyl, and the like.
[0259] Here, "saturated heterocycle" means that the heterocycle defined above does not contain unsaturated bonds, such as double bonds. For example, "nitrogen-containing saturated heterocyclic group" can be
[0260] In this disclosure, the terms "substituted" or "substituted" or "substituted" are used interchangeably and refer to the replacement of one or more hydrogen atoms or groups with a selected group of the specified group, provided that the normal valence of the specified atom is not exceeded. Wherein, the substituents may be one or more, each of which is independently selected from deuterium, halogen, alkyl, cycloalkyl, alkoxy, aryl, heteroaryl, and heterocyclyl, wherein halogen, alkyl, cycloalkyl, alkoxy, aryl, heteroaryl, and heterocyclyl are as defined above.
[0261] From all the above descriptions, it is obvious to a person skilled in the art that any group whose name is a composite name, such as "cycloalkylalkyl", should refer to the moiety derived therefrom conventionally from left to right, such as from "alkyl" substituted by "cycloalkyl", wherein cycloalkyl and alkyl are as defined above. BRIEF DESCRIPTION OF THE DRAWINGS
[0262] Figure 1 shows the expression of CD33 target on the surface of A431 cells;
[0263] Figure 2 shows the expression of target CD33 on the surface of HEL92.1.7 cells;
[0264] Figure 3 shows the expression of CD33, a target on the surface of CMK cells;
[0265] Figure 4 shows the expression of target CD33 on the surface of U937 cells;
[0266] Figure 5 shows the expression of target CD33 on the surface of HL-60 cells;
[0267] Figures 6, 7, 8, 9, and 10 respectively show the results of killing experiments using four AML cell lines and A431 as CD33 target cells;
[0268] Figure 11 shows the expression of target Trop2 on the surface of N87 cells;
[0269] Figure 12 shows the expression of target Trop2 on the surface of A431+SW620 heterogeneous tumor cells;
[0270] Figures 13 and 14 respectively show the results of cell killing experiments expressing two different Trop2 targets;
[0271] Figures 15, 16, 17, and 18 respectively show the results of cell killing experiments with four different HER2 target expression;
[0272] Figures 19 and 20 respectively show the binding of anti-CD33 antibody drug conjugates (single-drug ADC and dual-drug ADC) to recombinant human CD33 protein. Beneficial effects
[0273] 1. In the ADC drugs disclosed herein, the concept of synthetic lethality is used to damage cancer cells while inhibiting the repair of cancer cell damage, thereby leading to cancer cell death. This concept uses less cell damage repair inhibitors than combined drug therapy, further reducing possible damage to normal cells.
[0274] 2. The ADCs disclosed herein with damage repair inhibitors can increase the sensitivity of moderately toxic toxin drugs (or increase the availability or administration of moderately toxic drugs).
[0275] 3. In the ADC with damage repair inhibitor disclosed herein, when the toxin drug used is a highly toxic compound, the window can be expanded. DETAILED DESCRIPTION
[0276] The present disclosure will be further described below by way of specific embodiments, but this is not intended to limit the present disclosure. Those skilled in the art may make various modifications or improvements based on the teachings of the present disclosure without departing from the basic concept and scope of the present disclosure. Reagents or instruments used without indicating the manufacturer are conventional products that can be purchased commercially.
[0277] This application discloses an antibody-drug conjugate that simultaneously couples a targeted protein to a DNA damage repair inhibitor and another drug. Specifically, in some embodiments, the application couples one of the DNA damage inhibitor and the other drug to the original interchain disulfide bond cysteine (Cys) residue of the targeted protein; and the remaining other drug is linked to the cysteine (Cys) residue of the targeted protein by site-specific conjugation. The mechanism of site-specific conjugation is to site-specifically mutate some of the original amino acids on the targeted protein into cysteine or to site-specifically insert cysteine or a cysteine-containing polypeptide.
[0278] In this disclosure, the abbreviations of some drugs and their corresponding structural formulas are shown below:
[0279] XD-01:
[0280] MMAE:
[0281] PNU159682:
[0282] PBD:
[0283] CBI:
[0284] PBD-CBI:
[0285] AMCA4:
[0286] VE-822:
[0287] Talazoparib:
[0288] E7016:
[0289] niraparib:
[0290] Rucaparib:
[0291] BGB-290:
[0292] CEP-9722:
[0293] Ceralasertib(AZD6738):
[0294] VX-803(M4344):
[0295] AZ20:
[0296] Elimusertib(BAY-1895344):
[0297] Adavosertib(MK-1775,AZD1775):
[0298] SRA737(CCT245737,PNT-737):
[0299] Prexasertib (LY2606368, ACR368):
[0300] CHIR-124:
[0301] PF-477736 (PF-736):
[0302] MK-8776 (SCH 900776):
[0303] GDC-0575 (ARRY-575, RG7741):
[0304] CC-115:
[0305] AZD7648:
[0306] Nedisertib (M3814, Peposertib):
[0307] KU-0060648:
[0308] VX-984(M9831):
[0309] The present invention will be further explained below with reference to specific examples. Unless otherwise specified, all reaction raw materials can be purchased commercially.
[0310] Example 1
[0311] Synthesis of compound A-4:
[0312] Step 1: Synthesis of Compound A-1
[0313] In a 2L single-necked flask, add 5-tert-butyl Fmoc-L-glutamic acid ester (SM1, 200g, 470mmol), propargylamine (28.5g, 517mmol), and 400mL of DMF. Dissolve the mixture and cool to approximately 0°C in an ice-water bath. Add EDCI (108.2g, 564mmol), HOBt (76.2g, 564mmol), and DIEA (117mL, 705mmol). Warm the mixture to room temperature and react for 2h. Monitor the reaction endpoint by TLC. After the reaction, pour the reaction solution into 2L of water and extract three times with ethyl acetate (500mL x 3). The organic phases are combined, washed twice with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. The sodium sulfate is filtered out, and the filtrate is concentrated to obtain the crude product. The crude product is purified with petroleum ether / ethyl acetate (2 / 1) to obtain compound A-1 (100.9g) in a 48% yield. LCMS: [M+H] + =463.2.
[0314] Step 2: Synthesis of Compound A-2
[0315] In a 1L single-necked flask, add A-1 (100.0 g), dissolve in 500 mL of dichloromethane, and then add 200 mL of trifluoroacetic acid. React at room temperature for 2 hours, and monitor the reaction endpoint by TLC. After the reaction is completed, concentrate to remove DCM and some trifluoroacetic acid to obtain a crude product. Methyl tert-ether is added to the crude product to precipitate a white solid, which is filtered and dried to obtain compound A-2 (77.5 g) with a yield of 87%. LCMS: [MH] — =405.1.
[0316] Step 3: Synthesis of Compound A-3
[0317] In a 2L single-necked flask, A-2 (77.0 g) was added and dissolved in 150 mL of DMF. 38 mL of diethylamine was then added and allowed to react at room temperature for 2 h. The reaction endpoint was monitored by TLC. After the reaction was completed, 800 mL of tertiary methyl ether was added to the reaction solution to precipitate a white solid, which was filtered and dried to obtain compound A-3 (33.7 g) with a yield of 96.6%. LCMS: [MH] — =183.1.
[0318] Step 4: Synthesis of compound A-4
[0319] In a 100 mL single-necked bottle, compound A-3 (10.02 g, 54.4 mmol) and compound SM2 (14.48 g, 36.3 mmol) [refer to the synthesis method of patent CN108452321] were added and dissolved in 100 mL of DMF. EEDQ (13.5 g, 54.8 mmol) was then added and reacted at room temperature for 2 h. The reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by preparative liquid chromatography to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound A-4 (9.94 g) with a yield of 48%. LCMS: [MH] — =563.2.
[0320] Example 2
[0321] Synthesis of compound A-6:
[0322] Step 1: Synthesis of Compound A-5
[0323] In a 250 mL single-necked flask, compound A-4 (6.38 g, 11.3 mmol) and compound VAPAB-OH (3.98 g, 13.56 mmol) were added and dissolved in 50 mL of DMF. EDCI (2.6 g, 13.56 mmol), HOBt (1.83 g, 13.56 mmol), and DIEA (2.8 mL, 16.96 mmol) were then added. The mixture was reacted at room temperature for 2 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by preparative liquid chromatography to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound A-5 (5.07 g) as a white solid with a yield of 53%. LCMS: [M+H] + =840.4.
[0324] Step 2: Synthesis of Compound A-6
[0325] In a 100 mL single-necked flask, compound A-5 (3.94 g, 4.7 mmol) and di(p-nitrobenzene) carbonate (NPC, 8.56 g, 28.14 mmol) were added and dissolved in 40 mL of DMF. DIEA (2.32 mL, 14.07 mmol) was then added and allowed to react at room temperature for 1.5 h. The reaction endpoint was monitored by TLC. After the reaction, the reaction solution was purified by column chromatography to obtain compound A-6 (3.9 g) with a yield of 83%. LCMS: [M+H] + =1005.4.
[0326] Example 3
[0327] Synthesis of compound A-8:
[0328] Step 1: Synthesis of Compound A-7
[0329] In a 50 mL single-necked flask, compound A-4 (2.5 g, 4.4 mmol) and compound VCPAB-OH (2.0 g, 5.28 mmol) were added and dissolved in 25 mL of DMF. EDCI (1.01 g, 5.28 mmol), HOBt (0.72 g, 5.28 mmol), and DIEA (1.1 mL, 6.6 mmol) were then added. The mixture was reacted at room temperature for 2 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by preparative liquid chromatography to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound A-7 (1.96 g) as a white solid with a yield of 48%. LCMS: [M+H] + =926.4.
[0330] Step 2: Synthesis of Compound A-8
[0331] In a 50 mL single-necked flask, compound A-7 (1.85 g, 2.0 mmol) and di(p-nitrobenzene) carbonate (NPC, 3.65 g, 12.0 mmol) were added and dissolved in 15 mL of DMF. DIEA (1.05 mL, 6.0 mmol) was then added and allowed to react at room temperature for 1.5 h. The reaction endpoint was monitored by TLC. After completion of the reaction, the reaction solution was purified by column chromatography to obtain compound A-8 (1.77 g) with a yield of 81%. LCMS: [M+H] + =1091.5.
[0332] Example 4
[0333] Synthesis of compound B-1:
[0334] In a 25 mL single-necked bottle, β-cyclodextrin ammonia (mono(6-amino-6-deoxy)-β-cyclodextrin, purchased, 2.0 g, 1.76 mmol) and compound N3-PEG2-COOH (purchased, 428.8 mg, 2.11 mmol) were added and dissolved in 7 mL of DMF. EDCI (405 mg, 2.11 mmol) was then added and allowed to react at room temperature for 2 h. The system turned from turbid to clear. The reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by preparative liquid chromatography to obtain a product preparation solution. The preparation solution was lyophilized to obtain a white solid compound B-1 (1.68 g) with a yield of 72%. LCMS: [M+H] + =1319.5.
[0335] Example 5
[0336] Synthesis of compound B-2:
[0337] In a 100 mL single-necked bottle, meglumine (3.0 g, 6.4 mmol) and compound N3-PEG8-COOH (purchased, 1.5 g, 7.68 mmol) were added and dissolved in 24 mL of DMF. PyBOP (4.0 g, 7.68 mmol) and DIEA (1.58 mL, 9.6 mmol) were then added. The reaction was allowed to react at room temperature for 2 h. The reaction was monitored by HPLC. When no significant progress was observed, the reaction was terminated. The reaction solution was purified by preparative liquid chromatography to obtain a product preparation solution. The preparation solution was lyophilized to obtain a light yellow oil B-2 (3.27 g) with a yield of 32%. LCMS: [M+H] + =645.3.
[0338] Example 6
[0339] Synthesis of compound B-3:
[0340] Maltodextrin (7.0 g, 19.5 mmol) was dissolved in 70 mL of anhydrous methanol at room temperature, and the atmosphere in the system was replaced with nitrogen three times. The mixture was heated under reflux overnight after molecular sieve removal, cooled to room temperature, and 1-amino-11-azido-3,6,9-trioxoundecane was added. The mixture was stirred at room temperature for 24 h. The reaction solution was directly concentrated under reduced pressure. The crude product was dissolved in 5 mL of methanol, and then 30 mL of chloroform and 100 mL of tetrahydrofuran were added in sequence. After stirring, the mixture was allowed to stand to obtain a white solid. The mixture was filtered, and the filter cake was rinsed twice with tetrahydrofuran. The obtained white solid was dissolved in 30 mL of water and lyophilized to obtain 5.6 g of white solid compound B-3; LC-MS m / z (M+H) + :559.3.
[0341] Example 7
[0342] Synthesis of compound R01':
[0343] Step 1: Synthesis of compound 1
[0344] In a 25 mL single-necked vial, compound VE-822 (840.5 mg, 1.81 mmol), A-6 (1.9231 g, 1.90 mmol), and HOBt (369.0 mg, 2.72 mmol) were added and dissolved in 10 mL of DMF. DIEA (300 μL, 1.81 mmol) was then added and allowed to react at room temperature for 1 h. The reaction was monitored by TLC. After completion of the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 1 (1.9270 g) as a yellow solid with a yield of 80%. LCMS: [M+H] + =1329.6.
[0345] Step 2: Synthesis of compound 2
[0346] Compound 1 (604.2 mg, 0.45 mmol), zinc bromide (2017.6 mg, 9.09 mmol), and 18 mL of CH3NO2 were added to a 100 mL single-necked flask to form a uniform yellow turbid solution. The mixture was reacted at 40°C for 0.5 h. The solvent was then concentrated at 45°C under reduced pressure with a water pump. The reaction endpoint was monitored by HPLC. The concentrate was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 2 (225.6 mg) in a yield of 42%. LCMS: [M+H] + =1173.4.
[0347] Step 3: Synthesis of compound R01'
[0348] Compound 2 (27.73 mg, 0.02 mmol), β-cyclodextrin azide (purchased, 33.0 mg, 0.026 mmol), 2 mL of DMF, and 0.2 mL of water were added to a 10 mL PE tube. CuSO4·5H2O (38.07 mg, 0.075 mmol) and sodium ascorbate (21.99 mg, 0.075 mmol) were then added. The mixture was allowed to react at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound R01' (46.11 mg) with a yield of 83.6%. LC-MS: [M+2H] 2+ =1167.4.
[0349] Example 8
[0350] Synthesis of compound R01-1':
[0351] In a 50 mL round-bottom flask, compound 2 (379.8 mg, 0.32 mmol), B-1 (480.65 mg, 0.364 mmol), 4 mL of DMF, and 0.4 mL of water were added for dissolution. CuSO4·5H2O (262.8 mg, 1.1 mmol) and sodium ascorbate (206.1 mg, 1.04 mmol) were then added. The mixture was allowed to react at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound R01-1' (386.4 mg) in a yield of 48%. LC-MS: [M+2H] 2+ =1247.0.
[0352] Example 9
[0353] Synthesis of compound R02':
[0354] In a 50 mL round-bottom flask, compound 2 (105.2 mg, 0.09 mmol), B-2 (72.3 mg, 0.112 mmol), 4 mL DMF, and 0.8 mL water were added for dissolution. CuSO4·5H2O (69.9 mg, 0.28 mmol) and sodium ascorbate (59.46 mg, 0.30 mmol) were then added. The mixture was reacted at room temperature for 0.5 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound R02' (120.8 mg) in a yield of 74%. LC-MS: [M+2H] 2+ =909.4.
[0355] Example 10
[0356] Synthesis of compound R01-4':
[0357] Step 1: Synthesis of compound 3
[0358] In a 10 mL PE tube, compound VE-822 (28.77 mg, 0.062 mmol), A-8 (70.77 g, 0.065 mmol), and HOBt (13.62 mg, 0.10 mmol) were added and dissolved in 1 mL of DMF. DIEA (10 uL, 0.062 mmol) was then added and allowed to react at room temperature for 1 h. The reaction was monitored by TLC. After completion of the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 3 (75.44 mg) as a yellow solid in an 86% yield. LCMS: [M+H] + =1415.6.
[0359] Step 2: Synthesis of compound 4
[0360] To a 25 mL round-bottom flask, compound 3 (75.0 mg, 0.053 mmol), zinc bromide (238.95 mg, 1.07 mmol), and 7.5 mL of CH3NO2 were added. The mixture was reacted at 40°C for 0.5 h. The solvent was then concentrated at 45°C under reduced pressure. The reaction endpoint was monitored by HPLC. The concentrate was purified by HPLC to obtain a preparative solution. The preparative solution was lyophilized to obtain compound 4 (18.82 mg) in a 28% yield. LCMS: [M+H] + =1259.5.
[0361] Step 3: Synthesis of compound R01-4'
[0362] Compound 4 (18.5 mg, 0.015 mmol), β-cyclodextrin azide (19.5 mg, 0.017 mmol), 1 mL of DMF, and 0.1 mL of water were added to a 10 mL PE tube. CuSO4·5H2O (5.12 mg, 0.02 mmol) and sodium ascorbate (4.02 mg, 0.02 mmol) were then added. The mixture was allowed to react at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound R01-4' (21.6 mg) in a 60% yield. LC-MS: [M+2H] 2+ =1210.3.
[0363] Example 11
[0364] Synthesis of compound Ex01':
[0365] Compound Ex01' was synthesized with reference to our company's patent CN113827736A.
[0366] Example 12
[0367] Synthesis of compound 10:
[0368] Step 1: Synthesis of compound 6
[0369] Compound 5 (1.0 g, 1.51 mmol, see patent WO2020063676A1) was added to a 50 mL single-necked vial. Dissolve in 15 mL of DMF and add 1.0 g of 5% Pd / C. Hydrogenate at room temperature for 2 h. Monitor the reaction endpoint by HPLC. Filter and reserve the filtrate, designated Filtrate 1.
[0370] Step 2: Synthesis of compound 7
[0371] In another 50 mL single-necked flask, add compound A-4 (0.85 g, 1.51 mmol) and dissolve in 15 mL of DMF. Add DCC (1.55 g, 7.56 mmol) and pentafluorophenol (0.31 g, 1.66 mmol) under ice-water bath. Warm to room temperature and react for 2 h. Monitor the reaction endpoint by TLC. After the reaction is complete, filter to obtain the filtrate, which is recorded as filtrate 2.
[0372] Step 3: Synthesis of Compound 8
[0373] In an ice-water bath, filtrate 1 was added to filtrate 2, and the mixture was allowed to react at room temperature for 1 h. The reaction endpoint was monitored by HPLC. After the reaction was complete, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain 805 mg of white solid compound 8, with a yield of 54%. LC-MS m / z (M+H)+ :985.2.
[0374] Step 4: Synthesis of compound 9
[0375] Compound 8 (500 mg, 0.51 mmol) was added to a 50 mL single-necked flask and dissolved in 10 mL of DMF. PyBOP (396 mg, 0.76 mmol), HOBt (103 mg, 0.76 mmol), and exitecan mesylate (270 mg, 0.51 mmol) were added sequentially under an ice-water bath. DIEA (252 uL, 1.52 mmol) was then added. The mixture was allowed to warm to room temperature for 2 h. The reaction endpoint was monitored by HPLC. After the reaction was complete, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain 500 mg of white solid compound 9, with a yield of 70%. LC-MS m / z (M+H) + :1402.2.
[0376] Step 5: Synthesis of compound 10
[0377] To a 100 mL round-bottom flask, compound 9 (450.1 mg, 0.32 mmol), zinc bromide (1448.2 mg, 6.42 mmol), and 30 mL of CH3NO2 were added. The mixture was reacted at 45°C for 0.5 h. The solvent was then concentrated at 45°C under reduced pressure. The reaction endpoint was monitored by HPLC. The concentrate was purified by HPLC to obtain a preparative solution. The preparative solution was lyophilized to obtain compound 10 (203.9 mg) in a 51% yield. LCMS: [M+H] + =1245.6.
[0378] Example 13
[0379] Synthesis of compound Ex02':
[0380] Compound 10 (100.1 mg, 0.081 mmol) and β-cyclodextrin azide (100.5 mg, 0.087 mmol) were added to a 10 mL PE tube, and then 2 mL DMF was added to dissolve the solution. 0.2 mL purified water was added to dissolve the solution, and CuSO4·5H2O (20.1 mg, 0.081 mmol) and sodium ascorbate (16.0 mg, 0.081 mmol) were added. The reaction was allowed to react at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound Ex02' (91.6 mg) with a yield of 47%. LC-MS: [M+2H] 2+ =1203.0.
[0381] Example 14
[0382] Synthesis of compound Ex03'
[0383] Referring to the synthetic route of Example 9, compound Ex03' (57.8 mg) was obtained from compound 10 and compound B-2; LC-MS m / z (M+2H) 2+ :1023.9.
[0384] Example 15
[0385] Synthesis of compound Ex04'
[0386] Referring to the synthetic route of Example 8, compound Ex04' (125.2 mg) was synthesized from compound 10 and compound B-1; LC-MS m / z (M+2H) 2+ :1282.8.
[0387] Example 16
[0388] Synthesis of compound PB01':
[0389] Step 1: Synthesis of compound 12
[0390] In a 25 mL single-necked vial, compound A-6 (100 mg, 0.099 mmol) and compound 11 (purchased, 31.3 mg, 0.099 mmol) were added and dissolved in 5 mL of DMF. DIEA (32.8 uL, 0.199 mmol) was then added and allowed to react at room temperature for 2 h. The reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 12 (75.8 mg) with a yield of 64.5%. LCMS: [M+H] + =1181.5.
[0391] Step 2: Synthesis of compound 13
[0392] Compound 12 (75 mg, 0.063 mmol) and zinc bromide (285.7 mg, 1.27 mmol) were added to a 25 mL single-necked flask and dissolved in 10 mL of CH3NO2. The mixture was allowed to react at room temperature for 2 h, and the reaction endpoint was monitored by HPLC. After the reaction, the solvent was removed by vacuum concentration at 45°C to obtain a residue. The residue was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound 13 (49.6 mg) with a yield of 76.3%. LCMS: [M+H] + =1025.4.
[0393] Step 3: Synthesis of compound PB01'
[0394] In a 25 mL single-necked vial, compound 13 (25 mg, 0.024 mmol), compound B-2 (15.8 mg, 0.024 mmol), 2 mL of DMF, and 1 mL of water were added for dissolution. CuSO4·5H2O (6.7 mg, 0.026 mmol) and sodium ascorbate (5.3 mg, 0.026 mmol) were then added. The mixture was reacted at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound PB01' (33.1 mg) with a yield of 82.5%. LC-MS: [M+2H] 2+ m / z=835.5.
[0395] Example 17
[0396] Synthesis of compound PB02':
[0397] Referring to the synthetic route of Example 8, compound PB02' (43.6 mg) was synthesized from compound 13 and compound B-1 with a yield of 77.5%. LC-MS: [M+2H] 2+ m / z=1173.1.
[0398] Example 18
[0399] Synthesis of compound CBI01':
[0400] Step 1: Synthesis of compound 15
[0401] In a 25 mL single-necked vial, compound A-6 (231.6 mg, 0.23 mmol) and compound 14 (purchased, 50.0 mg, 0.22 mmol) were added and dissolved in 10 mL of DMF. DIEA (42 uL, 0.25 mmol) was then added and allowed to react at room temperature for 1 h. The reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 15 (190.9 mg) with a yield of 78%. LCMS: [M+H] + =1113.5.
[0402] Step 2: Synthesis of compound 16
[0403] Compound 15 (180.5 mg, 0.163 mmol) and zinc bromide (740.8 mg, 3.28 mmol) were added to a 50 mL single-necked bottle and dissolved in 10 mL of CH3NO2. The mixture was reacted at room temperature for 0.5 h. The solvent was removed by concentration at 45°C under reduced pressure to obtain a residue. The residue was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound 16 (73.8 mg) in a yield of 48%. LCMS: [M+H] + =957.2.
[0404] Step 3: Synthesis of compound CBI01'
[0405] In a 25 mL single-necked vial, compound 16 (30.5 mg, 0.032 mmol), compound B-3 (18.0 mg, 0.035 mmol), 2 mL of DMF, and 0.5 mL of water were added for dissolution. CuSO4·5H2O (8.0 mg, 0.032 mmol) and sodium ascorbate (6.4 mg, 0.032 mmol) were then added. The mixture was reacted at room temperature for 1 h, and the reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound CBI01' (29.5 mg) with a yield of 62.5%. LC-MS: [M+H] + m / z=1515.6.
[0406] Example 19
[0407] Synthesis of compound CBI02'
[0408] Referring to the synthetic route of Example 9, compound 16 and compound B-2 were used to obtain compound CBI02' (17.6 mg); LC-MS m / z (M+2H): 2+ :801.4.
[0409] Example 20
[0410] Synthesis of compound CBI03'
[0411] Referring to the synthetic route of Example 8, compound CBI03' (12.5 mg) was synthesized from compound 16 and compound B-1; LC-MS m / z (M+2H) 2+ :1138.9.
[0412] Example 21
[0413] Synthesis of compound 25:
[0414] Step 1: Synthesis of compound 18
[0415] Compound 18 was obtained by referring to the synthesis of "Compound 26" in patent CN102933236A. In a 250mL three-necked flask, compound 17 (3g, 6.7mmol) and 50mL of anhydrous THF were added. Under nitrogen protection, an ice-water bath was maintained at 0°C, and solid sodium borohydride (384mg, 10.2mmol) was added. The reaction was allowed to react at 0°C for 30min, then warmed to room temperature for 2h. The reaction endpoint was monitored by TLC. After the reaction, the reaction solution was poured into ice water and slowly added with 50mL of water to quench the reaction. 1N dilute HCl was then added until bubbling ceased. Ethyl acetate was added (60mL*3) for extraction. The organic phases were combined, washed twice with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (DCM / MeOH = 20:1-5:1) to obtain compound 18 (2.08g, yellow solid) with a yield of 74.3%. LC-MS: [M+H] + =415.1.
[0416] Step 2: Synthesis of compound 19
[0417] Compound 18 (2 g, 4.8 mmol), TBSCl (1.32 g, 8.8 mmol), imidazole (1.2 g, 17.6 mmol) were added to a 100 mL single-necked flask and dissolved in 15 mL of anhydrous DMF. The mixture was reacted at room temperature for 3 h, and the reaction endpoint was monitored by TLC. After the reaction was completed, the reaction mixture was poured into 30 mL of water and extracted with DCM (25 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (PE / EA = 5:1-1:2) to obtain compound 19 (2.28 g, yellow solid) with a yield of 89.3%. LC-MS: [M+H] + =529.2.
[0418] Step 3: Synthesis of Compound 20
[0419] Compound 19 (2.2 g, 4.16 mmol) and 30 mL of 5% formic acid / methanol solution were added to a 100 mL single-necked flask. The mixture was cooled to below 5°C in an ice bath. Zinc powder (5.44 g, 83.2 mmol) was slowly added with stirring, and the mixture was allowed to warm to room temperature for 1 h. The reaction endpoint was monitored by TLC. After the reaction, the mixture was filtered while hot, and the filter cake was washed with a small amount of methanol. The filtrate was adjusted to pH 7 with saturated sodium bicarbonate solution, then concentrated under reduced pressure at 45°C to remove the solvent, yielding a brownish-yellow oil. 60 mL of DCM was added, and the organic layer was separated, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure at 45°C to obtain the crude product. The crude product was purified by column chromatography (PE:EA = 1:1-1:3) to afford compound 20 (1.87 g, pale yellow solid) in a 90.1% yield. LC-MS: [M+H] + =500.2.
[0420] Step 4: Synthesis of compound 21
[0421] Compound 20 (1.8 g, 3.6 mmol) and Fmoc-VA-PABO-PNP (purchased, 2.45 g, 3.6 mmol) were added to a 50 mL single-necked vial. Dissolved in 15 mL of DMF, DIEA (893 μL, 5.4 mmol) was then added. The mixture was allowed to react at room temperature for 2 h. The reaction endpoint was monitored by HPLC. After completion of the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution, which was then lyophilized to obtain compound 21 (2.94 g, light yellow solid). The yield was 78.3%. LC-MS: [M+H] + =1040.5.
[0422] Step 5: Synthesis of compound 22
[0423] Compound 21 (2.9 g, 2.78 mmol) was added to a 50 mL single-necked bottle, dissolved in 8 mL of THF and 8 mL of water, and then 20 mL of glacial acetic acid was added. The reaction was allowed to react at room temperature and the reaction endpoint was monitored by HPLC. After the reaction was completed, the reaction solution was slowly dripped into 400 mL of saturated sodium bicarbonate solution and extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (DCM / MeOH = 10:1-5:1) to obtain compound 22 (1.94 g, light yellow solid) with a yield of 75%. LC-MS: [M+H] + =926.3.
[0424] Step 6: Synthesis of compound 23
[0425] Compound 22 (1.9 g, 2.0 mmol) was added to a 100 mL three-necked flask and dissolved in 40 mL of anhydrous DCM. Under nitrogen protection, Dess-Martin periodinane (0.93 g, 2.2 mmol) was added and reacted at room temperature for 4 h. The reaction endpoint was monitored by TLC. After the reaction was completed, the mixture was filtered and the filtrate was washed with saturated sodium bicarbonate solution, water, and saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by high-performance liquid chromatography to obtain a product preparation solution, which was lyophilized to obtain compound 23 (1.61 g, off-white solid) with a yield of 85%. LC-MS: [M+H] + =924.4.
[0426] Step 7: Synthesis of compound 24
[0427] Compound 23 (1.5 g, 1.62 mmol) was added to a 50 mL single-necked bottle, dissolved in 15 mL DMF, and then 3 mL diethylamine was added. The reaction was allowed to react at room temperature for 1 h, and the reaction endpoint was monitored by TLC. After the reaction was completed, the reaction solution was poured into 100 mL tertiary methyl ether, the solid precipitated, and filtered to obtain the deprotected product. The deprotected product was dissolved in 15 mL DMF, and compound A-4 (0.92 g, 1.62 mmol) and EEDQ (0.48 g, 1.94 mmol) were added. The reaction was allowed to react at room temperature for 2 h, and the reaction endpoint was monitored by HPLC. After the reaction was completed, the reaction solution was purified by high-performance liquid chromatography to obtain a product preparation solution, which was lyophilized to obtain compound 24 (1.30 g, off-white solid) with a yield of 64.2%. LC-MS: [M+H] + =1248.5.
[0428] Step 8: Synthesis of compound 25
[0429] Compound 24 (500 mg, 0.4 mmol) was added to a 50 mL single-necked flask and dissolved in 5 mL of DCM. Trifluoroacetic acid (5 mL) was then added and allowed to react at room temperature for 1 h. The reaction endpoint was monitored by HPLC. After the reaction, the solvent was removed by vacuum concentration at 45°C to obtain a residue. The residue was purified by HPLC to obtain a product preparation solution, which was lyophilized to obtain compound 25 (294 mg) with a yield of 67.4%. LC-MS: [M+H] + =1092.4.
[0430] Example 22
[0431] Synthesis of compound PBD01'
[0432] Referring to the synthetic route of Example 9, compound 25 and compound B-2 were used to obtain compound PBD01' (45.2 mg); LC-MS m / z (M+2H) 2+ :869.0.
[0433] Example 23
[0434] Synthesis of compound PBD02'
[0435] Referring to the synthetic route of Example 18, compound 25 and compound B-3 were used to obtain compound PBD02' (31.6 mg); LC-MS m / z (M+2H) 2+ :825.8.
[0436] Example 24
[0437] Synthesis of compound 27:
[0438] Step 1: Synthesis of compound 26
[0439] In a 50 mL single-necked bottle, compound A-6 (2.0012 g, 1.99 mmol) and MMAE (purchased, 1.36 g, 1.90 mmol) were added and dissolved in 20 mL of DMF. DIEA (0.48 mL, 2.80 mmol) was then added and allowed to react at room temperature for 2 h. The reaction endpoint was monitored by HPLC. After the reaction, the reaction solution was purified by HPLC to obtain a product preparation solution. The preparation solution was lyophilized to obtain compound 26 (2.21 g) with a yield of 73.5%. LCMS: [M+H] + =1584.0.
[0440] Step 2: Synthesis of compound 27
[0441] Compound 26 (2.0 g, 1.26 mmol) and zinc bromide (5.69 g, 25.25 mmol) were added to a 100 mL single-necked flask and dissolved in 40 mL of CH3NO2. The mixture was reacted in an oil bath at 40°C for 0.5 h. The solvent was then concentrated at 45°C under reduced pressure to obtain a residue. The residue was purified by HPLC to obtain a preparative solution of the product. The preparative solution was lyophilized to obtain compound 27 (773.5 mg) in a yield of 43%. LCMS: [M+H] + =1427.8.
[0442] Example 25
[0443] Synthesis of compound M01':
[0444] Referring to the synthetic route of Example 13, compound M01' (85.5 mg) was synthesized using compound 27 and β-cyclodextrin azide as raw materials; LC-MS m / z (M+2H) 2+ :1294.5.
[0445] Example 26
[0446] Synthesis of compound M02':
[0447] Referring to the synthetic route of Example 8, compound M02' (293.2 mg) was obtained from compound 27 and compound B-1; LC-MS m / z (M+2H) 2+ :1374.0.
[0448] Example 27
[0449] Synthesis of compound M03':
[0450] Referring to the synthetic route of Example 9, compound 27 and compound B-2 were used to obtain compound M03' (98.2 mg); LC-MS m / z (M+2H) 2+ :1037.1.
[0451] Example 28
[0452] Antibody sequences used:
[0453] Sequence of anti-CD33 antibody ANTI-CD33
[0454] >Light chain -LC
[0455] >Heavy chain-HC
[0456] Sequence of anti-Trop2 antibody ANTI-Trop2-1
[0457] >Light chain -LC
[0458] >Heavy chain-HC
[0459] Sequence of anti-Trop2 antibody ANTI-Trop2-2
[0460] >Light chain -LC
[0461] >Heavy chain-HC
[0462] Sequence of the anti-HER2 antibody Trastuzumab (Tras)
[0463] >Light chain -LC
[0464] >Heavy chain-HC
[0465] Sequence of the anti-HER2 antibody Tras-016
[0466] >Light chain -LC
[0467] >Heavy chain-HC
[0468] Example 29
[0469] Preparation of single-drug ADC (DAR=8) (general method)
[0470] Prepare antibody-drug conjugate samples by conjugating Antibody A with L1-D1 or L2-D2:
[0471] After cell expression and purification by Protein A affinity chromatography and molecular sieve chromatography, Antibody A was replaced in 20 mM NaAc-HAc, pH 6.0 buffer and concentrated or diluted to a protein concentration of 5 mg / mL. L1-D1 or L2-D2 was dissolved in N,N-dimethylacetamide (DMA) to 10 mg / mL before use.
[0472] To open the interchain disulfide bonds of antibody A, 15-25 times the molecular weight of tris(2-carboxyethyl)phosphine (TCEP) was added and allowed to react at room temperature for 2 hours. 15-25 times the molecular weight of L1-D1 or L2-D2 solution was added and allowed to react at room temperature for 2 hours. After the reaction, the solution was replaced using a 30 kDa ultrafiltration concentrator to remove uncoupled L1-D1 or L2-D2, thereby obtaining antibody A-D1 (DAR = 8) or antibody A-D2 (8) samples.
[0473] Example 30
[0474] Preparation of single-drug ADC (DAR=10) and dual-drug ADC (DAR=2+8) (general method)
[0475] Prepare antibody B-D2(2)-D1(8), antibody B-D1(2)-D2(8), antibody B-D1(10) or antibody B-D2(10) conjugate samples by conjugating antibody B with L1-D1 and L2-D2:
[0476] After cell expression and purification by Protein A affinity chromatography and molecular sieve chromatography, Antibody B was replaced in 20 mM NaAc-HAc, pH 6.0 buffer and concentrated or diluted to a protein concentration of 5 mg / mL. L1-D1 and L2-D2 were dissolved in DMA to 10 mg / mL for later use.
[0477] First, add 15-25 times the molecular weight of TCEP and react at room temperature for 2-4 hours to reduce the disulfide bonds between the antibody B chains and the cysteine side chains introduced into the antibody to sulfhydryl groups. After the reaction is completed, use a 30KDa ultrafiltration concentrator to replace the liquid and remove impurities in the reaction liquid to obtain the reduced antibody B sample.
[0478] According to the molecular ratio, 15-25 times of dehydroascorbic acid (dHA) solution is added to the reduced sample solution of antibody B, and the solution is reacted at room temperature for 2-4 hours to oxidize the opened sulfhydryl groups on the antibody into interchain disulfide bonds. Then, 5-15 times of L2-D2 or L1-D1 solution is added to react with the disulfide bonds introduced on the antibody at room temperature for 2 hours. After the reaction is completed, the solution is replaced using a 30KDa ultrafiltration concentrator to remove the unconjugated L2-D2 or L1-D1, thereby obtaining the antibody B-D2(2) or antibody B-D1(2) conjugate sample.
[0479] According to the molecular ratio, 15-25 times of TCEP is added to antibody B-D2(2) or antibody B-D1(2), and the reaction is carried out at room temperature for 2 hours to open the interchain disulfide bonds of the antibody on antibody B-D2(2) or antibody B-D1(2). Then, 15-25 times of L1-D1 or L2-D2 solution is added to react with the interchain disulfide bonds of the antibody at room temperature for 2 hours. After the reaction is completed, the solution is replaced using a 30KDa ultrafiltration concentration tube to remove unreacted L1-D1 or L2-D2, thereby obtaining antibody B-D2(2)-D1(8), antibody B-D1(2)-D2(8), antibody B-D1(10) or antibody B-D2(10) conjugates.
[0480] Referring to the above method, the following ADCs were prepared and synthesized using antibodies ANTI-CD33, ANTI-Trop2-1, ANTI-Trop2-2, Tras, and Tras-016:
[0481] Test Example 1: Cell killing experiment with dual-toxic ADC targeting CD33, Trop2, and HER2
[0482] 1. Equipment, consumables and reagents
[0483] Reagents
[0484] equipment
[0485] cell
[0486] 2. Sample information
[0487] 3. Principles and methods
[0488] 3.1. Principle of MTS cell killing assay
[0489] To test drug efficacy at the cellular level, cells are plated at a specific density in a 96-well plate. After the cells have attached (usually requiring at least four hours), serial dilutions of the drug are added to each well of the plate and allowed to react for a specified period of time to kill the cells. After the drug reaction period has expired, a specific amount of MTS is added and incubated at 37°C, 5% CO₂ for 1-4 hours. After developing the color reaction using MTS reagent, the absorbance at 490 nm is measured using a microplate reader, and the IC50 for cell killing is calculated.
[0490] MTS (3-(4,5-diethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-etrazolium, inner salt) is a new-generation tetrazolium blue salt compound. Its reduced formazan product is more water-soluble and stable, and develops color more quickly. It operates on the same principle as MTT: it is reduced by various dehydrogenases in the mitochondria of living cells to form their own colored formazan products. The color intensity of these products is highly correlated with the viable cell count of certain sensitive cell lines within a certain range.
[0491] 3.2. Methods
[0492] Sample preparation
[0493] Before adding the drug, according to the concentration of each test sample, use preheated 1% FBS culture medium to prepare the drug at a starting concentration of 5.0 μM (5× mother liquor concentration), and then dilute it 10 times in a gradient concentration, for a total of 8 test points, and place it aside. During the preparation process, each concentration must be mixed with an oscillator for 2 to 3 seconds at a time, with an interval of 1 second, and then oscillated, and repeated 2 to 3 times.
[0494] The final concentrations of antibodies and antibody-drug conjugates were 0 (Vehicle), 0.6 pM, 4.25 pM, 29.75 pM, 0.21 nM, 1.46 nM, 10.20 nM, 71.43 nM, and 500 nM;
[0495] Experimental procedures
[0496] 1) Cell Thawing: After preheating the culture medium in a 37°C water bath, transfer 9 mL of the medium to a centrifuge tube for later use. Remove the cells from liquid nitrogen and immediately thaw them by rapidly shaking at 37°C. Transfer the cells to a pre-prepared centrifuge tube and centrifuge at 1000 rpm for 3 min at room temperature. Discard the supernatant and resuspend the pellet in 1 mL of complete culture medium. Be gentle during this process to avoid introducing bubbles to minimize cell damage. Transfer the cells to a culture flask and culture them in a cell culture incubator at 37°C, 5% CO2, and 95% relative humidity. After 24 h of recovery, observe the cell status and replace the culture medium with fresh one promptly for subculture and cell counting.
[0497] 2) Cell Plating: All cell lines used for in vitro efficacy testing must be subcultured for three generations after recovery. Based on the validated cell plating density, dilute the cell suspension with cell culture medium containing 1% FBS and gently add 80 μL / well to a 96-well plate. Finally, seal the edges of the 96-well plate with 200 μL of sterile PBS or sterile ddH2O. Place the plate in a CO2 incubator and culture overnight.
[0498] 3) Using three replicates per concentration for each test molecule, add 20 μL / well of the drug at 5x the expected concentration to each well (e.g., wells B2 to B10, C2 to C10, D2 to D10, or wells E2 to E10, F2 to F10, and G2 to G10). Initially, the drug concentration is 1000 nM. A single 96-well plate can accommodate two test drugs. Typically, wells B11, C11, and D11 contain cells and are supplemented with 20 μL of 1% FBS medium as negative controls. Wells E11, F11, and G11 serve as blank controls, containing no cells and 100 μL of 1% FBS medium.
[0499] 4) Generally, the ADC drug treatment time is 5 days, during which the drug effect is observed using an inverted microscope at 24h, 48h and 72h after drug addition.
[0500] 5) Remove CellTiter from -20°C Thaw the One Solution Reagen MTS reagent at room temperature away from light, vortex thoroughly to mix, and then add 20 μL of CellTiter® per 100 μL of cell culture volume along the side of the well in a biosafety cabinet. One Solution Reagen MTS reagent: Add MTS reagent in equal proportions to different cell culture volumes, gently tap the plate to mix the MTS solution evenly, and then place it in a cell culture incubator away from light and incubate for 2h-4h.
[0501] 6) After the reaction is completed, the 96-well plate is removed and the absorbance at OD490 nm is measured in a microplate reader. The data is then recorded, organized, and stored.
[0502] 7) Data were processed and analyzed according to the following formula to calculate the cell viability at different drug concentrations.
[0503] 8) Graphpad Prism 9.0 data processing software four-parameter logic fitting module was used to process the curve fitting and obtain
[0504] Get IC50.
[0505] 4. Results and Analysis
[0506] 4.1.CD33 cell killing assay:
[0507] The target cells were HEL92.1.7, a CD33-highly expressing acute myeloid leukemia cell line; CMK, U937, and HL-60, a CD33-intermediately expressing acute myeloid leukemia cell line; and A431, a skin squamous cell carcinoma cell line that did not express CD33. Flow cytometry was used to determine CD33 expression levels on the target cells. The cell cytotoxicity of the CD33 dual-toxic ADC was then evaluated using the MTS assay. See Figures 1-10 and Tables 1 and 2.
[0508] Table 1 CD33 expression in the tested cells
[0509] Table 2 IC50 of the test substances at the cellular level
[0510] in conclusion:
[0511] Under the experimental conditions, in the killing experiments of 4 AML cell lines and 1 epithelial squamous cell carcinoma cell model,
[0512] 1. Naked anti-CD33 ANTI-CD33-mAb has no significant killing activity against multiple AML cell lines;
[0513] 2. In CD33 high-expressing, medium-expressing and CD33-negative cell lines, the dual-toxic ADC obtained by simultaneously coupling the anti-CD33 antibody with a low-toxic repair inhibitor and a highly toxic damaging agent: ANTI-CD33-R01-1(2)-Ex01(8) was significantly more sensitive to multiple AML tumor cells in vitro than the single-toxin ADC obtained by coupling only the highly toxic damaging agent: ANTI-CD33-Ex01(10).
[0514] 4.2.Trop2 cell killing experiment:
[0515] Using the Trop2-high-expressing cell line N87 and the heterogeneous tumor cancer cell line A431+SW620 as target cells, flow cytometry was first used to determine Trop2 expression levels in the target cells. The cell cytotoxicity of the Trop2 dual-toxic ADC was then evaluated using the MTS assay. See Figures 11-14 and Tables 3 and 4.
[0516] Table 3 Trop2 expression in the tested cells
[0517] Table 4 IC50 of the test substances at the cellular level
[0518] in conclusion:
[0519] Under the experimental conditions, in the killing experiments of two cell models,
[0520] 1. Trop2 naked anti-ANTI-Trop2-1-mAb and ANTI-Trop2-2-mAb had no significant killing activity against the two cell lines;
[0521] 2. In Trop2-overexpressing cell lines and negative cell lines, the dual-toxic ADCs obtained by coupling anti-Trop2 antibodies with high-killing activity damaging agents and low-toxicity and low-activity repair inhibitors: ANTI-Trop2-2-R01-1(2)-Ex01(8) and ANTI-Trop2-2-R02(2)-Ex01(8) showed significantly better in vitro sensitivity to tumor cells than the single-toxic ADC ANTI-Trop2-1-Ex01(8) coupled only with high-killing activity damaging agents, and significantly better than the single-toxic ADC ANTI-Trop2-2-Ex01(10).
[0522] 4.3.HER2 cell killing experiment:
[0523] SK-BR-3, H1975, MDA-MB-453, and MDA-MB-468 cell lines, each expressing varying degrees of HER2, were used as target cells. HER2 expression levels in the target cells were first determined by flow cytometry, and the cell cytotoxicity of the HER2 dual-drug ADC was then evaluated using the MTS assay. See Figures 15-18 and Tables 5 and 6.
[0524] Table 5 HER2 expression in the tested cells
[0525] Table 6 IC50 of the test substances at the cellular level
[0526] in conclusion:
[0527] Under the experimental conditions, in the killing experiments of 4 cell models,
[0528] 1. Monoclonal ADCs derived from anti-HER2 antibodies coupled with highly cytotoxic agents: Tras-Ex01 (DAR8) and Tras-016-Ex01 (DAR10) showed significant differences in their cytotoxicity against tumor cells, with the activity at DAR of 10 significantly higher than that at DAR of 8.
[0529] 2. In cell lines with different HER2 expression, the dual-toxic ADCs obtained by coupling anti-HER2 antibodies with high-killing activity damaging agents and low-toxicity and low-activity repair inhibitors: Tras-016-R01-1(2)-Ex01(8) and Tras-016-R02(2)-Ex01(8) were significantly more sensitive to tumor cells in vitro than the single-toxic ADC Tras-Ex01(DAR8) which was only coupled with high-killing activity damaging agents, and the activity was significantly better than the single-toxic ADC Tras-016-Ex01(DAR10).
[0530] Test Example 2: ELISA detection of the binding of anti-CD33 antibody drug conjugates to recombinant human CD33 protein:
[0531] The binding capacity of antibodies and antigens can be preliminarily determined using ELISA. Here, we immobilized recombinant human CD33 protein on an enzyme strip and added a series of CD33 antibody concentration gradients for detection.
[0532] 1. Coating: Dilute CD33 to 0.5 μg / mL in 1× PBS, add 100 μL per well, and coat overnight at 4°C.
[0533] 2. Washing: Wash the plate three times with washing buffer (1×PBS + 0.05% Tween 20), 200 μL per well, and let it stand for 1 min each time.
[0534] 3. Blocking: After patting the plate wash solution dry for the third time, add blocking buffer (1×PBS+0.05% Tween20+1% BSA), 200 μL per well, and block at 37°C for 1 hour.
[0535] 4. Washing: Wash the plate three times with 200 μL of washing buffer per well, and let it stand for 1 min each time.
[0536] 5. Primary Antibody Loading: Dilute the antibody-drug conjugate (same as in Test Example 1) from 2 μg / mL in a three-fold gradient using sample diluent (1× PBS + 0.05% Tween 20 + 1% BSA). Wash the plate three times with plate wash buffer, 200 μL per well, and let stand for 1 min each time.
[0537] 6. Secondary antibody loading: Dilute Solarbio rabbit anti-human 1:10000 with assay buffer (1×PBS+0.05% Tween20+1% BSA) to 100 μL per well and incubate at 37°C for 1 hour.
[0538] 7. Washing: Wash the plate three times with 200 μL of washing buffer per well, and let it stand for 1 min each time.
[0539] 8. Reading: Add TMB colorimetric solution (50 μL per well). After 7 min of color development, add 2 M H2SO4 (50 μL per well) to terminate the color development. Read the plate at 450 nm using a microplate reader.
[0540] The experimental results are shown in Figures 19 and 20.
[0541] Conclusion: The binding ability of anti-CD33 antibody drug conjugates single-drug ADC: ANTI-CD33-Ex01(10), dual-drug ADC: ANTI-CD33-R01-1(2)-Ex01(8), ANTI-CD33-Ex01(2)-R01-1(8) to recombinant human CD33 protein was basically the same as that of naked anti-ANTI-CD33 to recombinant human CD33 protein, with no significant difference.
[0542] Test Example 3 Plasma Stability Test of Anti-CD33 Antibodies and Antibody-Drug Conjugates
[0543] A mixture of ANTI-CD-33 naked antibody and ADC (ANTI-CD33-R01-1(2)-Ex01(8)) and IgG-depleted human plasma was prepared to a final concentration of 0.6 mg / ml. The mixture was placed in a water bath in a 37°C incubator and incubated for 0, 3, and 7 days. Unincubated and unextracted controls and unincubated and extracted controls were also set. The incubated samples were analyzed using the SEC-HPLC method. The results are shown in Table 7.
[0544] Table 7. Plasma stability data
[0545] Conclusion: The ADC disclosed in the present invention has good plasma stability, low degradation rate, low aggregation rate, and the excellent property of high monomer rate.
[0546] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and variations can be made to the details based on all the teachings disclosed, and these changes are within the scope of protection of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.
Claims
1. A ligand-drug conjugate of formula I or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, in: Ab is a targeting moiety selected from an antibody, an antibody fragment, a targeting protein or an Fc-fusion protein; D1 is a first drug, which is connected to L1; D2 is a second drug, the second drug is selected from a DNA damage repair inhibitor, and the second drug is connected to L2; L1 is a first linking unit, which connects the first drug and the targeting moiety; L2 is a second linking unit, which connects the second drug and the targeting moiety; m is an integer selected from 0 to 20; n is selected from an integer of 1-20.
2. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to claim 1, wherein: The second drug is selected from ATR inhibitors, ATM inhibitors, PARP inhibitors, WEE1 inhibitors, CHK1 inhibitors, and DNA-PK inhibitors; Preferably, the ATR inhibitor is selected from Or a compound represented by formula A or a deuterated product thereof: in, X1 is selected from O, S, NH, CH2; Preferably, X1 is selected from O, S; More preferably, X1 is O; X2 and X3 are each independently selected from N and CH; Preferably, X2 is N, X3 is CH; X4, X5, and X6 are each independently selected from N and CH; Preferably, X4 and X6 are N, and X5 is CH; X7 is selected from N, C(R0); Preferably, X7 is C(R0); R0 is selected from hydrogen, C1-C6 alkyl, R b R a N-; Preferably, R0 is R b R a N-; R a , R b Each is independently selected from hydrogen, C1-C6 alkyl; Preferably, R a , R b All are hydrogen; R1, R2, R3, R4, R5 are each independently selected from hydrogen, C1-C6 alkyl, Preferably, R1, R2, R3, R4, and R5 are each independently selected from hydrogen, More preferably, any one of R1, R2, R3, R4, and R5 is The rest is hydrogen; Most preferably, R3 is R1, R2, R4, R5 are hydrogen; R c Selected from hydrogen, C1-C6 alkyl; Preferably, R c Selected from C1-C6 alkyl; More preferably, R c is isopropyl; R6, R7, R8, and R9 are each independently selected from hydrogen, C1-C6 alkyl; Preferably, R6, R7, R8, R9 are hydrogen; R d Selected from hydrogen, C1-C6 alkyl; Preferably, R d Selected from C1-C6 alkyl; More preferably, R d is methyl; p is selected from 1, 2, 3, 4, 5, 6; Preferably, p is selected from 1, 2, 3; More preferably, p is 1; More preferably, the compound shown in formula A is Preferably, the PARP inhibitor is selected from Preferably, the ATM inhibitor is selected from Preferably, the WEE1 inhibitor is selected from Preferably, the CHK1 inhibitor is selected from Preferably, the DNA-PK1 inhibitor is selected from 3. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 2, wherein: The second connecting unit is a breakable or non-breakable connecting unit; Preferably, L2 is L 21 -L 22 -L 23 -L 24 , and L 24 Connected to D2, L 21 Linked to Ab (preferably, L 21 via sulfhydryl coupling to Ab), L 21 Selected from The N-terminal and L 22 Connected, L 22 Selected from: The carbonyl end is connected to L 23 Connected; L 23 is selected from an amino acid residue or a peptide residue consisting of 2-10 amino acid residues, and the carbonyl end is connected to L 24 Connected; Preferably, L 23 is a peptide residue consisting of 2-4 (preferably 2) amino acid residues, and the carbonyl end is connected to L 24 Preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, lysine, citrulline, serine, glutamic acid, and aspartic acid, and more preferably, the amino acid is selected from valine, alanine, and citrulline; More preferably, L 23 is selected from valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and the carbonyl end is connected to L 24 Connected; Most preferably, L 23 Selected from The carbonyl end is connected to L 24 Connected; or direct key, and L 24 for When , the carbonyl end is connected to D2; Preferably, L2 is selected from: And the carbonyl end is connected to D2.
4. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 3, wherein: D2-L2-Selected from:
5. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 4, wherein: The first drug is selected from, but not limited to, a tubulin binding agent, a DNA damaging agent, an enzyme inhibitor, an immunomodulator, a peptide or a nucleotide; Preferably, the first drug is selected from: a) Alkylating agents, PBD and its derivatives, chlorphenazone, chlorprenazine, cyclophosphamide, dacarbazine, estradiol nitrogen mustard, ifosfamide, mechlorethamine, dimethoxamine hydrochloride, nitrogen oxide mustard, amlodipine hydrochloride, mycophenolic acid, dulcitol, pipobroman, new nitrogen mustard, phenamic acid, phenamic acid, thiotepa, trofosfamide, uracil; CC-1065; duocarcin; benzodiazepine dimer; nitrosourea; alkyl sulfonates; triazenes; platinum-containing compounds; aziridines, such as chromanone, carlosin, metodipa and uredopa; ethyleneimine and methylmelamine, including hexamethylmelamine, triethylenetriamine, triethylphosphoramide, triethylenethiophosphoramide and trishydroxymethylmethylamine and their derivatives and deuterated derivatives; b) Plant alkaloids, vinca alkaloids; taxoids and their analogs; maytansine alkaloids and their analogs; cryptophycin; epothilone, damascene, dimolide, bryozoan lactone, dolastatin, auristatins, tubulysin, cephalostatin, pancratistatin, sarcodictyin, spongestatin, Monomethyl auristatin E (MMAE), Monomethyl auristatin F (MMAF), maytansine alkaloids (e.g. Maytansine DM1, Maytansine DM4), amatoxin and its derivatives and deuterated derivatives; c) DNA topoisomerase inhibitors, etoposide pentazocine, 9-aminocamptothecin, camptothecin, clenatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, nosocomialin, retinoic acid, teniposide, topotecan, 9-nitrocamptothecin, SN38, mitomycin and its derivatives and deuterated derivatives; d) Antimetabolites, antifolates, DHFR inhibitors; MP dehydrogenase inhibitors; ribonucleotide reductase inhibitors; pyrimidine analogs, uracil analogs; cytosine analogs; purine analogs; folic acid supplements; e) Hormone therapy agents, receptor antagonists, antiestrogens, LHRH agonists; antiandrogens; retinoids, vitamin D3 analogs; photodynamic therapy agents; cytokines, human proteins including TNF and their derivatives and deuterated derivatives; f) Kinase inhibitors, BIBW2992, imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080, mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab Antibodies, panitumumab, ispins and their derivatives and deuterated derivatives; g) antibiotics, ethylenediamine antibiotics, aclacinomycins, actinomycins, anthramycins, azaserine, bleomycin, canomomycin, kanamycin, carminamicin, carminamicin, doxorubicin, morpholinodoxorubicin, 2-pyrrolinodoxorubicin and deoxydaunorubicin, epirubicin, aclarubicin, idarubicin, marcomycin, mycophenolic acid, lopimycin, peplomycin, puromycin, triferric doxorubicin, streptozotocin, streptozotocin, tuberculocidin, ubenimex, jinsistatin, daurubicin, PNU-159682 and their derivatives and deuterated derivatives; h) polyketides, in particular bullatacin and bullatacinone; gemcitabine, cyclooxygenase, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allocatin-7, Xegeva, Provenge, Yervoy, prenylation inhibitors, dopaminergic neurotoxins, actinomycin, bleomycin, anthracyclines, doxorubicin, idarubicin, epirubicin, doxycycline, mitoxantrone, MDR inhibitors, Ca2+ ATPase inhibitors, histone deacetylase inhibitors; celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A; Antiadrenal drugs, such as aminoglutethimide, mitotane, trilostane, aceglucuronolide, aldehyde phosphamide, aminolevulinic acid, amsacrine, arabinoside, bestrAbuci, bisantrene, edatraxate, defofamine, mecocin, diazocine, eflornithine, elfornithine, elliptonium acetate, ethylgluconate, gallium nitrate, cytosine, hydroxyurea, ibandronate, lentinan, lonidamine, mitoguanidine, mitoxantrone, mopidarol, diamine nitrazolium, pentostatin, methamine nitrogen mustard, pirarubicin, podophyllic acid, 2-ethylhydrazine, methylprocarbazine; Piperazinedionepropane; rhizoxin; sirozolin; spirogermanium; spore azolic acid; triimine quinone; trichlorotriethylamine; trichothecenes, polyurethanes, siRNA and antisense drugs and their derivatives and deuterated derivatives; More preferably, the first drug D1 is selected from a camptothecin structure compound or a deuterated compound thereof; Preferably, the camptothecin structure compound has a structure shown in Formula B, in: The chiral carbon atom No. 1 connected to the N atom has an absolute chirality of R configuration or S configuration; R' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, aryl, substituted aryl or heteroaryl; Preferably, R' is selected from hydrogen, C1-C6 alkyl; More preferably, R' is hydrogen; R 1' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, carboxyl, heterocyclyl, aryl, substituted aryl or heteroaryl; Preferably, R 1' Selected from hydrogen, C1-C6 alkyl; More preferably, R 1' Selected from C1-C6 alkyl; Most preferably, R 1' is methyl; R 2' is selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, deuterated alkyl, cycloalkylalkyl, alkoxyalkyl, carboxyl, heterocyclyl, aryl, substituted aryl or heteroaryl; Preferably, R 2' is selected from halogen; More preferably, R 2' For fluorine; X' is selected from -C(O)-(CR 3' R 4' )t-CR a' R b' -O-、-C(O)-(CR 3' R 4' )t-CR a' R b' -NH- or -C(O)-(CR 3' R 4' )t-CR a' R b' -S-, preferably, the carbonyl end is connected to the N atom; Preferably, X' is selected from -C(O)-(CR 3' R 4' )t-CR a' R b' -O-, preferably, the carbonyl end is connected to the N atom; More preferably, X' is selected from -C(O)-CR a' R b' -O-, preferably, the carbonyl end is connected to the N atom; R a' is selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl, substituted aryl or heteroaryl; Preferably, R a' Selected from hydrogen, C1-C6 alkyl; More preferably, R a' is hydrogen; R b' is selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl, substituted aryl or heteroaryl; Preferably, R b' is selected from hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl; More preferably, R b' is selected from hydrogen, deuterium, methyl, cyclopropyl, trifluoromethyl; Or, R a' , R b' and the carbon atom to which it is attached constitutes a C3-6 cycloalkyl group, a cycloalkylalkyl group or a heterocyclic group; R 3' , R 4' are the same or different and are each independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, alkoxy, hydroxy, amino, cyano, nitro, hydroxyalkyl, cycloalkyl or heterocyclyl; Or, R 3' , R 4' and the carbon atom to which it is attached constitutes a C3-6 cycloalkyl group, a cycloalkylalkyl group or a heterocyclic group; The wavy line on the right side connected to X' is connected to L1; t is an integer selected from 0 to 4; Preferably, t is 0; Preferably, X' is selected from the following structures without limitation: in: The chiral carbon atom No. 2 has an absolute chirality of R configuration or S configuration; The left wavy line is connected to N of the compound represented by formula B, and the right wavy line is connected to L1; Preferably, the compound represented by formula B is selected from Preferably, the first drug is selected from 6. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 5, wherein: The first connecting unit is a breakable or non-breakable connecting unit; Preferably, L1 is L 11 -L 12 -L 13 -L 14 , and L 14 Connected to D1, L 11 Linked to Ab (preferably, L 11 via sulfhydryl coupling to Ab), L 11 Selected from The N-terminal and L 12 Connected, L 12 Selected from: The carbonyl end is connected to L 13 or L 14 Connected; L 13 is selected from a direct bond, an amino acid residue or a peptide residue consisting of 2-10 amino acid residues, and L 13 When selected from amino acid residues or peptide residues consisting of 2-10 amino acid residues, the carbonyl end is connected to L 14 Connected; Preferably, L 13 is selected from a direct bond, an amino acid residue, a peptide residue consisting of 2-4 amino acid residues, and L 13 When selected from amino acid residues, peptide residues consisting of 2-4 amino acid residues, the carbonyl end is connected to L 14 Preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, lysine, citrulline, serine, glutamic acid, and aspartic acid, and more preferably, the amino acid is selected from valine, alanine, phenylalanine, glycine, citrulline, and lysine; More preferably, L 13 is selected from a direct bond, lysine, glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and L 13 When selected from lysine, glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), the carbonyl end is adjacent to L 14 Connected; Most preferably, L 13 Select from direct key, And L 13 Selected from When the carbonyl end is 14 Connected; L 14 Selected from The amino terminus is connected to L 13 or L 12 connected, the carbonyl end or carbon end is connected to D1; Preferably, L1 is selected from: The carbonyl end or The carbon end at one end is connected to D1.
7. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 6, wherein: D1-L1-Selected from:
8. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 7, wherein: m is an integer selected from 1 to 10; Preferably, m is selected from an integer of 2-8; More preferably, m is selected from 2, 4, 8; Alternatively, n is selected from an integer of 1-10; Or preferably, n is selected from an integer of 2-8; Or more preferably, n is selected from 2, 4, and 8.
9. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 8, wherein: Ab is selected from a murine antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an antibody fragment, a bispecific antibody and a multispecific antibody, preferably, Ab forms a linker with the linker through its cysteine thiol group (-SH); Preferably, Ab is an antibody, which is a monoclonal antibody selected from: anti-EGFRvIII antibody, anti-DLL-3 antibody, anti-PSMA antibody, anti-CD70 antibody, anti-MUC16 antibody, anti-ENPP3 antibody, anti-TDGF1 antibody, anti-ETBR antibody, anti-MSLN antibody, anti-TIM-1 antibody, anti-LRRC15 antibody, anti-LIV-1 antibody, anti-CanAg / AFP antibody, anti-cladin 18.2 antibody, anti-Mesothelin antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-c-MET antibody, anti-SLITRK6 antibody, anti-KIT / CD117 antibody, anti-STEAP1 antibody, anti-SLAMF7 / CS1 antibody, anti-NaPi2B / SLC34A2 antibody, anti-GPNMB antibody, anti-HER3 (ErbB3) antibody, anti-MUC1 / CD227 antibody, anti-AXL antibody, anti-CD166 antibody, anti-B7-H3 (CD276) antibody, anti-PTK7 / CCK4 antibody, anti-PRLR antibody, anti-EFNA4 antibody, anti-5T4 antibody, anti-NOTCH3 antibody, anti-Nectin 4 antibody, anti-TROP-2 antibody, anti-CD142 antibody, anti-CA6 antibody, anti-GPR20 antibody, anti-CD174 antibody, anti-CD71 antibody, anti-EphA2 antibody, anti-LYPD3 antibody, anti-FGFR2 antibody, anti-FGFR3 antibody, anti-FRα antibody, anti-CEACAMs antibody, anti-GCC antibody, anti-Integrin Av antibody, anti-CAIX antibody, anti-P-cadherin antibody, anti-GD3 antibody, anti-Cadherin 6 antibody, anti-LAMP1 antibody, anti-FLT3 antibody, anti-BCMA antibody, anti-CD79b antibody, anti-CD19 antibody, anti-CD33 antibody, anti-CD56 antibody, anti-CD74 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD37 antibody, anti-CD47 antibody, anti-CD138 antibody, anti-CD352 antibody, anti-CD25 antibody or anti-CD123 antibody.
10. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 9, wherein: Both D1-L1- and D2-L2- are coupled to Ab via sulfhydryl groups; Preferably, the source of the thiol group is selected from: the thiol group on the cysteine residue formed after the original interchain disulfide bond of the targeting moiety is reduced, the thiol group on the cysteine after site-directed mutation of some original amino acids on the targeting moiety into cysteine, the thiol group on the cysteine after site-directed insertion of cysteine into the targeting moiety, and the thiol group on the cysteine after site-directed insertion of a cysteine-containing polypeptide into the targeting moiety; Preferably, D1-L1- and D2-L2- are coupled to Ab via thiol groups from different sources, respectively; Preferably, any one of D1-L1- and D2-L2- is coupled to Ab through the thiol group on the cysteine residue formed after the original interchain disulfide bond of the targeting portion is reduced, and the other is coupled to Ab through the thiol group on the cysteine after site-directed mutation of some original amino acids on the targeting portion into cysteine, or after site-directed insertion of cysteine into the targeting portion, or after site-directed insertion of a cysteine-containing polypeptide into the targeting portion.
11. The ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 10, wherein: The ligand drug conjugate is selected from: Ab-R01(2)-Ex01(8), Ab-R01(8)-Ex01(2), Ab-R01(4)-Ex01(4), Ab-R01(4)-Ex01(8), Ab-R01(8)-Ex01(4), Ab-R01(2)-Ex02(8), Ab-R01(8)-Ex02(2), Ab-R01(4)-Ex02(4), Ab-R01(2)-Ex03(8), Ab-R01(8)-Ex03(2), Ab-R01(4)-Ex03(4), Ab-R01(2)-Ex04(8), Ab-R01(8)-Ex04(2), Ab-R01(4)-Ex04(4), Ab-R01(2)-Ex05(8), Ab-R01(8)-Ex05(2), Ab-R01(4)-Ex05(4), Ab-R01(2)-Ex06(8), Ab-R01(8)-Ex06(2), Ab-R01(4)-Ex06(4), Ab-R01-1(2)-Ex01(8), Ab-R01-1(8)-Ex01(2), Ab-R01-1(4)-Ex01(4), Ab-R01-1(8)-Ex01(4), Ab-R01-1(4)-Ex01(8), Ab-R01-1(2)-Ex02(8), Ab-R01-1(8)-Ex02(2), Ab-R01-1(4)-Ex02(4), Ab-R01-1(2)-Ex03(8), Ab-R01-1(8)-Ex03(2), Ab-R01-1(4)-Ex03(4), Ab-R01-1(2)-Ex04(8), Ab-R01-1(8)-Ex04(2), Ab-R01-1(4)-Ex04(4), Ab-R01-1(2)-Ex05(8), Ab-R01-1(8)-Ex05(2), Ab-R01-1(4)-Ex05(4), Ab-R01-1(2)-Ex06(8), Ab-R01-1(8)-Ex06(2), Ab-R01-1(4)-Ex06(4), Ab-R01-1(2)-PB01(8), Ab-R01-1(2)-PB02(8), Ab-R01-1(8)-PNU01(2), Ab-R01-1(8)-PNU02(2), Ab-R01-1(2)-CBI01(8), Ab-R01-1(2)-CBI02(8), Ab-R01-1(2)-CBI03(8), Ab-R01-1(2)-PBD01(8), Ab-R01-1(2)-PBD02(8), Ab-R01-1(2)-PBD-CBI01(8), Ab-R01-1(2)-PBD-CBI02(8), Ab-R01-1(8)-M01(2), Ab-R01-1(8)-M02(2), Ab-R01-1(8)-M03(2), Ab-AT01(2)-Ex01(8), Ab-AT02(2)-Ex01(8), Ab-AT03(2)-Ex01(8), Ab-AT04(2)-Ex01(8), Ab-TA01(2)-Ex01(8), Ab-VE01(2)-Ex01(8), Ab-E01(2)-Ex01(8), Ab-RU01(2)-Ex01(8), Ab-PA01(2)-Ex01(8), Ab-CEP01(2)-Ex01(8), Ab-TM01(2)-Ex01(8), Ab-TM02(2)-Ex01(8), Ab-WE01(2)-Ex01(8), Ab-CH01(2)-Ex01(8), Ab-CH02(2)-Ex01(8), Ab-CH03(2)-Ex01(8), Ab-CH04(2)-Ex01(8), Ab-DP01(2)-Ex01(8), Ab-DP02(2)-Ex01(8), Ab-DP03(2)-Ex01(8).
12. A drug-linker conjugate, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: The drug-linker conjugate is selected from the following:
13. A pharmaceutical composition comprising the ligand-drug conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to any one of claims 1 to 11, or the drug-linker conjugate or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate according to claim 12, and optionally one or more pharmaceutical excipients.
14. Use of the ligand-drug conjugate or its stereoisomer, prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate according to any one of claims 1 to 11, or the drug-linker conjugate or its stereoisomer, prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate according to claim 12, or the pharmaceutical composition according to claim 13 in the preparation of a medicament for treating and / or preventing a disease, wherein the disease is cancer; Preferably, the cancer is selected from skin cancer, lymphoma, esophageal cancer (e.g. esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g. small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, kidney cancer, solid tumors, non-Hodgkin's lymphoma, central nervous system tumors (e.g. glioma, glioblastoma multiforme, neuroblastoma, glioma or sarcoma), melanoma, prostate cancer, thyroid cancer, bone cancer, urethral cancer, salivary gland cancer, leukemia (e.g. acute myeloid leukemia), and other solid tumors and blood tumors; More preferably, the cancer is selected from lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, and kidney cancer.
